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There is one thing even more vital to science than intelligent methods;  
and that is, the sincere desire to find out the truth, whatever it may be.  
 
Charles Sanders Peirce 
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Aim and scopes of PhD thesis 
The work aimed at design and synthesis of chiral bidentate imidazolinium salts, able  
to coordinate to transition metal ions like ruthenium, rhodium and palladium. The chiral 
auxiliary ligands were expected to provide chiral surrounding of these metal ions by bidentate 
coordination through carbon and oxygen atoms. The attempts to synthesize complexes were 
performed in order to induce stereoselectivity of catalytic reactions in which the Ru(II), Rh(I) 
and Pd(II) complexes are involved. Current state of art within the subject of chiral ligands, 
catalytic complexes and catalytic processes is the matter of literature survey in introduction. 
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List of Abbreviations 
Ad  1-adamantyl 
Ar  aryl 
BINAM 1,1’-binaphthalenyl-2,2’-diamine 
BINAP 2,2’-Bis(diphenylphosphino)-1,1’-binaphthyl 
Bn  benzyl 
Boc  t-butoxycarbonyl 
bs  broad singlet 
cod   cyclooctadiene 
Cy  cycloxexyl 
d  doublet 
dba  trans, trans-dibenzylideneacetone 
DCC  N,N’-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DIPP  2,6-diisopropylphenyl 
DMSO dimethylsulfoxide 
ee  enantiomeric excess 
Et  ethyl 
KHMDS potassium bis(trimethylsilyl)amide 
m  multiplet 
Me  methyl 
Mes  mesityl, 2,4,6-trimethylphenyl 
Ms  mesyl or methanesulfonyl 
NBS  N-bromosuccinimide 
Ph  phenyl 
Pr  propyl 
Py   pyridine 
q  quartet 
R  alkil or aryl substituent 
R*  chiral substituent 
RCM  Ring Closing Metathesis 
ROP  Ring-opening polymerization 
8 
s  singlet 
SCE  saturated calomel electrode 
t  triplet 
tBu  t-butyl 
Tf  trifluoromethanesulfonyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TMS  trimethylsilyl  
Ts  tosyl, p-toluenesulfonyl 
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Part 1 
 
1. Literature survey 
 
1.1 Introduction 
 
N-heterocyclic carbenes (NHCs) are intriguing and long known singlet carbenes with 
the carbene incorporated in a nitrogen-containing heterocycle. The history  
of this interesting class of active species began in the early 1960`s after Wanzlick`s first 
studies on its reactivity and stability
1
. The first application of NHC as ligands for metal 
complexes was independently described by Wanzlick
2
 and Öfele3 in 1968. Afterwards, 
surprisingly, the field of NHCs as ligands in transition metal chemistry remained dormant 
until 1991 when Arduengo et al. reported first stable, crystalline 1,3-diadamantyl-2,3-dihydro-
1H-imidazol-2-ylidene, IAd, by deprotonation of the corresponding imidazolium salt
4
. This 
deprotonation method was later complemented by Kuhn et al.
5
 They use the reductive 
desulfurization of thiones for the preparation of stable imidazol-2-ylidenes. 
 
 
Fig. 1.1 Synthesis of first stable carbene. 
 
The isolation of first stable N-heterocyclic carbene demonstrated that free carbenes 
were not necessarily unstable intermediate and triggered an intensive research for additional 
stable NHCs. That led to developing and isolation not only of the variety of NHC with 
different ring and N-substituents but also NHC derivatives with different heteroatoms in the 
carbene ring and different N-heterocyclic ring size.  
Interesting features of N-heterocyclic carbenes such as their versatility, high electron 
donating ability and applicability in a broad range of transition metal mediated reactions 
10 
caused that this group of chemical compounds have become universal ancillary ligands  
in organometallic and inorganic coordination chemistry. General methods of their synthesis
6-10
 
as well as their coordination chemistry with metals
11-13
 have already been reviewed.  
Its comprehensive and extensive applications including e.g.: olefin polymerization and 
metathesis by Ru-based catalysts
14,15
, hydrosilylation by Rh and Pt carbene complexes
16
,  
Ir-catalyzed hydrogenation and hydrogen transfer
17
, Pd-catalyzed carbon-carbon coupling 
reactions
18
 and increasing number of enantioselective reactions
19
 are now well known. These 
types of reactions were traditionally carried out using phosphine-based systems but NHC 
complexes exhibit some more desirable properties not possessed by the former.  
Since this work concerns synthesis and development of chiral, bidentate imidazolinium salts 
as NHC precursors for Ru, Rh and Pd complexes and their potential catalytic activity the 
literature part will be focused on synthesis of NHC complexes with those metal ions. 
 
 
1.2 Synthesis of ligand precursors 
 
Access to N-heterocyclic carbenes is mostly controlled by the availability of suitable 
NHC precursors. Most of them are obtained by deprotonation of corresponding azolium salts 
e.g.: imidazolium, imidazolinium, benzimidazolium, triazolium, thiazolium or by reductive 
desulfurization of imidazol-, benzimidazol-, imidazolin-2-thiones. A comprehensive overview 
of NHCs and their complexes synthesis has been given by Hahn et al.
20
 On Fig. 1.2 are shown 
the most popular carbene moieties. 
11 
 
Fig. 1.2 Amino carbene frameworks. 
 
The majority of N-heterocyclic carbenes are based on five-membered ring systems and 
the most important and most often employed N-heterocyclic carbenes are imidazol-2-ylidenes 
and the dihydroimidazol-2-ylidenes. Therefore special emphasis is placed on synthetic path 
leading to unsaturated and saturated NHC ligands featuring a five-membered diamino-
heterocycle. Several methods have been described. Among them the alkylation of the nitrogen 
atoms of imidazole ring and building the imidazolium ring using symmetric or unsymmetrical 
synthetic procedure are two general methods (Scheme 1.1). 
12 
 
Scheme 1.1 General methods of synthesis of five-membered diaminoheterocycles. 
 
However a lot of other synthetic routes have been developed and employed. Some of them are 
shown in Scheme 1.2 and shortly described below. 
 
Scheme 1.2 Representative methods of synthesis of five-membered diaminoheterocycles. 
 
A very useful and versatile method is the ring closure reaction of easily accessible  
1,2-diamines into the aryl substituted imidazolium salts with orthoformate (Scheme 1.2 a).
21
 
The other interesting method is desulfuration of cyclic thiourea derivatives however it 
requires drastic conditions (Scheme 1.2 b).
22-24
  
Almost immediately after the reports on the preparation of the first stable NHCs a lot 
of reports regard modified N-heterocyclic carbenes or their corresponding salts such as: N,N`-
13 
donor functionalized
25-27
, bridged bis- or tris-imidazolium
28-30
, pincer ligands
31,32
  
or polydentate carbenes
33
 appeared. Some examples of these salts are shown in Fig. 1.3.  
 
Fig. 1.3 Examples of modified N-heterocyclic carbenes precursors. 
 
 
1.3 Synthesis of chiral N-heterocyclic carbenes precursors 
 
Natural continuation in developing of the N-heterocyclic carbenes was synthesis  
of chiral precursors and their metal complexes used as catalysts in enantioselective 
transformations. 
First attempts to use chiral NHC ligands in asymmetric catalysis started in the late 1990`s
34,35
 
but the rapid expansion of the field emerged not before publication by Burgess et al.
36
 in 2001 
14 
that reported the first truly efficient chiral catalyst containing chiral NHC moiety. The number 
of reports regarding synthesis of chiral NHCs precursors and their metal complexes were 
grown instantly and have been continuously reviewed. In 2003 a first overview of chiral 
NHCs in catalysis was published by Burgess et al.
37
 One year later a review by Gade et al.
38
 
appeared. This was followed up by reviews of synthesis and application of chiral NHC 
complexes in asymmetric catalysis by Mangeney et al.
39
 in 2005, Gade et al.
40
 and 
Douthwaite
41
 in 2007 and most recently Shi et al.
42
 in 2012. 
The four types of stable diaminocarbenes used for the synthesis of chiral complexes are 
shown in Fig. 1.4. 
 
Fig. 1.4 Stable diaminocarbenes. 
 
There are several available possibilities of introducing chirality into the N-heterocyclic 
carbene unit. It can be an asymmetric atom (central chirality), an axial chiral element  
(an atropisomeric substituent), planar chirality (planar chiral substituent) or their 
combinations. Gade et al.
38
 proposed the division of NHCs derivatives into five main families. 
Among them NHC ligands with a stereogenic center on one or two N-substituents or within 
the N-heterocycle, NHC ligands containing an element of axial or planar chirality and finally 
carbenes incorporating oxazoline unit and NHC ligands combining the former types can be 
distinguish. This convention will be retained in followed part of this chapter. 
 
1.3.1 N-heterocyclic carbene ligands with center of chirality on the  
N-substituents 
 
The first strategy of designing the chiral NHCs concerned the introduction  
of N-substituents containing a stereogenic center. Their general structure is shown in Fig. 1.5. 
15 
 
Fig. 1.5 General formula of the NHC ligands with chiral N-substituents. 
 
The first chiral imidazolium salts of this type were synthesized using the methods described 
by Herrmann and Enders in 1996.
34,35
 Symmetrical one were obtained using a one-pot 
condensation of chiral amines, paraformaldehyde and glyoxal under acidic conditions and  
the unsymmetrical are typically prepared by alkylating monosubstituted imidazoles with  
an appropriate alkyl halide. An imidazolium salt with an oxazoline unit was prepared  
by Herrmann, Burgess and Gade using the second method.
43-45
 Subsequently reports on other 
examples of imidazolium NHC precursors emerged. Five step synthesis using L-proline  
as starting material
46
 or an alkoxy-functionalized NHC obtained from a chiral epoxide
25
 were 
prepared. Moreover Burgess et al.
47
 and Douthwaite et al.
48,49
 have reported the synthesis of 
mono- and bidentate NHCs using trans-cyclohexanediamine as a building block. 
 
 
Fig. 1.6 Some examples of imidazolium salts with the stereogenic center on N-substituents. 
 
Synthesis and development of 1,4-disubstituted triazolium salts prepared from alkyl  
or aryl hydrazines followed by addition of chiral amines and 1,3,4-trisubstituted triazolium 
16 
salts prepared by cyclization with acetic anhydride of the in situ prepared reaction of N-alkyl-
N-formyl hydrazines with an imidoyl chloride were introduced by Enders et al.
50,51
. 
Simultaneously Leeper et al.
52
 has developed triazolinylidene with a bicyclic moiety. This 
class of ligands was further investigated and the derivatives with stereogenic center 
introduced in the side chain remote from the carbon joined to the N-atoms of the ring and 
functionalized ones were reported.
53,54
 
 
Fig. 1.7 Some examples of triazolium and benzimidazolium salts with the stereogenic center  
on N-substituents. 
 
Diver et al.
55,56
 reported synthesis of symmetrical and unsymmetrical chiral benzimidazolium 
salts starting from o-dibromobenzene. Later on in 2005 Shi et al.
57 reported the synthesis of 
racemic di-benzimidazolium salts obtained in four steps from (+/-) trans-cyclohexanediamine. 
Most recently the synthesis of chiral tridentate imidazolium salts using amino acids as starting 
material appeared.
58
  
Design and development of imidazolinium salts with the center of chirality on N-substituents 
made also an important contribution to the field. (-)-Isopinocamphenylamine and  
(+)-bornylamine derivatives were synthesized by Hartwig et al. in 2001.
59
 This group of NHC 
ligands will be further described in this dissertation (Chapter 1.4.2). 
NHC ligands possessing chiral N-substituents that have been reported and studied  
to date generally gives moderate results in asymmetric catalysis. They are efficient 
stereodirecting ligands if the N-substituents are either sterically demanding or locked in fixed 
conformations. Functionalized, polydentate ligands or ligands combining the chirality  
17 
on N-substituents with other types of chirality may have higher potential in the stereoselective 
catalytic transformations. 
 
 
1.3.2 N-heterocyclic carbene ligands with center of chirality within the  
N-heterocycle 
 
The second family of chiral azolium precursors, that possesses a chiral center within 
the N-heterocyclic ring, is represented by imidazolinylidenes. This class of compounds 
contains sp
3
-carbon atoms in the 4- and 5-position of the heterocycle therefore depending  
on the synthetic strategy one or two chiral center may be obtained (Fig. 1.8).  
 
Fig. 1.8 General formula of the NHC ligands containing stereogenic centers within N-heterocycle. 
 
This class of NHC ligands will be further and extensively described (Chapter 1.4.2). 
 
1.3.3 N-heterocyclic carbene ligands with an element of axial chirality 
 
A special case of chirality in which a molecule does not possess a stereogenic center 
but an axis of chirality is called axial chirality. The 1,1’-binaphthyl unit (shown in Fig. 1.9)  
is the most widely used structural moiety for the design of chiral ligands that convey 
asymmetric induction due to the configurationally stable atropoisomers formed as a result  
of the blocked rotation around the C-C axis linking the two naphthyl groups.
60
 During 
exploration of NHC ligands the idea of incorporating an axial chirality to the azolium salts 
moieties has emerged. The first chiral NHC ligand containing a 1,1’-binaphthyl unit 
connected via methylene linkers with two imidazole rings was reported in 2000 by Rajanbabu 
et al.
61
 Afterwards Shi et al.
62 have prepared in a four step synthesis starting from 
18 
enantiomerically pure BINAM the bidentate NHC ligand directly linked  
to the 1,1’-binaphthyl backbone (Fig. 1.9, right). 
 
Fig. 1.9 Axial chiral bis-carbene ligands based on the 1,1’-binaphthyl scaffold. 
 
Other interesting examples of this class of NHC ligands are reported by Hoveyda and 
Crabtree
63,64
 anionic bidentate carbene ligand combining an NHC unit with a phenolato donor 
(Fig. 1.10, left) or reported by Herrmann et al.
65
 carbene precursor with an axially chiral 
backbone made from benzannulated 1,1’-bipiperidine (Fig.1.10, right). 
 
Fig. 1.10 NHC ligands containing phenolato donor and 1,1’-bipiperidine unit. 
 
 
1.3.4 N-heterocyclic carbene ligands with an element of planar chirality 
 
Synthesis and development of NHC ligands containing an element of planar chirality 
has also been investigated (Fig. 1.11). Synthetic strategy of the first planar chiral NHC 
ligands starting from a chiral sulfoxide was reported in 2002 by Bolm et al.
66
 Shortly after  
19 
the chiral C2-symmetric carbene containing both planar chirality in the ferrocenyl units and 
chiral centers at the carbon atoms linking the ferrocene with N-heterocycle starting from Ugi`s 
chiral 1-ferrocenylethylamine was published by Togni et al.
67
 Three years later the same 
group reported synthesis of doubly ferrocenyl substituted imidazolium salt without  
the unnecessary methylene linker unit.
68
 
 
Fig. 1.11 Planar chiral and planar and central chiral, ferrocenyl (Fc) functionalized NHC ligands. 
 
An imidazolium and imidazolinium based NHC ligands containing paracyclophanes  
as a chiral planar elements have also been developed.
69,70
 
 
Figure 1.12 Planar chiral, [2.2]-paracyclophane functionalized NHC ligands. 
 
 
1.3.5 Other possible chiral N-heterocyclic carbene units 
 
Besides four previously mentioned families of NHC ligands the N-heterocyclic 
carbenes that combine in their structure two or more chiral elements of above mentioned 
types can be also marked out. They were mostly synthesized to obtain ligands that would 
possess potentially higher stereoselectivity towards selected reactions but also to expand  
the scope of this class of chemical compounds. Below in Fig. 1.13 a few examples of such 
more complex derivatives are shown.71,72 
20 
 
Fig. 1.13 Complex NHCs derivatives. 
 
 
1.4 Development and design of imidazolinium salts 
 
Recently, the saturated N-heterocyclic carbenes have received much attention, partially 
due to their increased Lewis basicity compared with their unsaturated counterparts.
11,73
 
Preparation of saturated imidazolin-2-ylidenes was first attempted by Wanzlick and 
Schikora
74 in early 1960. They have however reported synthesis of electron–rich 
vinyltetraamines instead of saturated carbenes via 1,1-elimination of chloroform from 
imidazoline derivatives. 
 
Scheme 1.3 Wanzlick`s and  Schikoras attempt to obtain saturated carbenes. 
 
Once again Arduengo
75 was the first who has reported stable crystalline imidazolin-2-
ylidene obtained by deprotonation of corresponding imidazolinium salt. 
 
Scheme 1.4 Synthesis of first stable crystalline imidazolin-2-ylidene. 
21 
Carbenes obtained by reductive desulfurization of imidazolin-1-thiones that led  
to the N,N’-substituted stable carbene or to the entetraamine with sterically less demanding 
N,N’-substituents23,76 and by 1,1-elimination reactions from imidazolidines77,78 were also 
reporter thereafter. 
 
1.4.1 Achiral imidazolinium salts 
 
Saturated imidazolinium salts can be obtained using various complementary synthetic 
routes. These methods are summarized on Scheme 1.5. 
 
Scheme 1.5 Synthetic routes for the preparation of imidazolinium salts. 
22 
Alkylation of dihydroimidazole or cyclization reactions between N,N’-dialkyl-α,β-ethyl-
diamines with orthoesters that gives symmetric and unsymmetrical imidazolinium salts were 
reported at the earliest
21,79,80
 (Scheme 1.5 a). 
The synthesis based on so-called multicomponent reaction (Scheme 1.5 b) was reported and 
further developed by Orru and co-workers.
81-83
 This reaction leads to unsymmetric 
imidazolinium salts with substituents at the C4 and C5 positions of heterocycle (Fig. 1.14). 
 
 
Fig. 1.14 Examples of imidazolinium salts obtained using multicomponent reaction. 
 
Other approach, presented by Grubbs
84 who reported a facile synthesis of symmetric and 
unsymmetric imidazolinium chlorides, involves reaction of formamidine with 1,2-
dichloroetane and base (Scheme 1.5 c and Fig. 1.15). 
 
Fig. 1.15 Examples of imidazolinium chlorides obtained using above mentioned method. 
 
Interesting synthesis of various imidazolinium salts via reaction of stable N-(2-iodoethyl)-
arylammonium salts with an amine and triethylformate was reported by Prasad et. al.
85
  
in 2009 (Scheme 1.5 d).  
23 
Moreover, in 2010 a one-pot electrosynthetic procedure giving imidazolinium cationic 
derivatives from secondary alkyl diamines in neutral media was reported.
86
 
 
Scheme 1.6 Electrosynthetic procedure for obtaining imidazolium and tetrahydropyrimidinium 
cationic derivatives. 
 
Although several synthetic routes were described the most of the reports regarding 
synthesis of imidazolinium salts are based on the general protocol shown in Scheme 1.5 a. 
Therefore number of synthetic routes leading to ethane-1,2-diamines have been developed 
and modified. The symmetric ones can be easily made via condensation of a variety  
of aromatic and aliphatic amines with glyoxal, followed by a reduction of the resulting Schiff 
bases
21,87
 or alternatively via nucleophilic substitution of 1,2-dibromoethane with aromatic 
amines
88
. The second option is applicable to a broader range of substrates than the imine 
route. 
 
Scheme 1.7 Synthesis of symmetrical 1,2-diamines. 
 
The synthesis of unsymmetric derivatives was also described using oxalyl chloride instead  
of glyoxal as starting material
89
 or commercially available diamines
90
. 
One-step reaction of various aryl bromides with 1,2-disubstituted ethane-1,2-diamines via  
the Pd-catalyzed amination
91
 was also introduced (Scheme 1.8). 
24 
 
Scheme 1.8 Synthesis of diamine precursors using Pd-catalyzed amination. 
 
On the other hand reaction of ethyl-2-chloro-2-oxoacetate with two different amines  
to form an oxalamide, followed by reduction with BH3
.
THF complex or LiAlH4 that gives 
ethane-1,2-diamines (Scheme 1.9), which can be cyclized to form unsymmetrically, chelating 
N,N’-substituted imidazolinium salts were reported in 2004.92,93 
 
Scheme 1.9 Synthesis of ethane-1,2-diamines. 
 
During the last ten years many researching groups were developing and describing 
imidazolinium NHC precursors obtained using above mentioned approaches. And so report 
regarding synthesis of unsymmetric imidazolinium salts with aryl alkyl N-substituents and 
their Ru-complexes used as metathesis catalysts were reported by Blechert group
94 in 2006 
(Fig. 1.16 a). Some new N,N’-bis(aryl)imidazolinium chlorides in which the N-aryl groups 
were substituted at the ortho and/or para positions with an alkyl or alkoxy group were 
reported shortly after
95
 (Fig. 1.16 b). Palladium complexes with these saturated NHCs bearing 
cyclometalated aromatic substituents have shown good activity in the Heck coupling of aryl 
bromides with acrylates. At the same time Plenio group
96
 reported synthesis of sulfonated, 
25 
water soluble imidazolinium salts (Fig. 1.16 c), which Pd-complexes were applied in aqueous 
Suzuki coupling reactions of aryl chlorides and synthesis of imidazolium and imidazolinium 
salts modified at the para position of aryl N-substituents with electron withdrawing 
substituents (Fig. 1.16 d) such as: -Et3N
+
, -SAr, –SO2Ar, -Cl, -F, -Br.
97,98
 
Symmetric and unsymmetric imidazolinium salts with N-aryl substituents were studied in 
Özdemir group.99 
 
Fig. 1.16 Examples of functionalized imidazolinium salts. 
 
Synthesis of easily accessible and stable imidazolin-2-ylidenes where the side chains 
were comprised of substituted naphthyl units have been reported by Dorta et al.
100,101
 They 
have explored this class of NHC ligands, investigated their catalytic potential and studied  
the effect of substituents on the syn-anti conformer ratio. They have found that NHC ligands 
with bulky substituents on position 2 or 2,7 of the naphthyl chains display a very strong 
preference to assume only the anti conformation.
102
 
 
Fig. 1.17 Syn and anti conformers of naphthyl-based imidazolin-2-ylidenes. 
 
26 
An interesting class of imidazolinium salts NHC precursors was reported by the group 
of Lüning.103 They had described a synthesis of concave bimacrocyclic imidazolinium 
chlorides obtained in a six-step reaction where the macrocyclizations of concave reagents was 
performed using ring closing metathesis reaction (Fig.1.18). Subsequently, transition metal 
complexes of Ag, Cu, Pd, Rh and Ir using these salts as ligands, were reported. The reactivity 
of Pd-complex was investigated in Mizoroki-Heck and Suzuki-Miyaura cross-coupling 
reactions giving comparable activities to the related non-macrocyclic palladium allyl 
complexes.
104,105
 
 
Fig. 1.18 General structure of concave imidazolinium salts.  
 
Annulated diaminocarbenes have also been studied. Reports by Ҫetinkaya et al. and 
further by Dastgir and Green present the Ag-, Pd-,Rh- Ir-complexes containing this class  
of NHC ligands (Fig. 1.19).
106
 Rh-complexes were tested for the hydroformylation  
of 1-octene and Pd-complexes have been tested for Suzuki coupling reaction and aryl 
amination reaction of activated and deactivated aryl halide. 
 
Fig. 1.19 Rh-, Pd-complexes containing annulated diaminocarbenes. 
 
The exploration of the field of imidazolinium-based NHC precursors was continued by  
Plenio group
107
, who obtained high molecular weight imidazolinium salts(800 and 1100 
27 
g/mol) with bulky –CH2NCy2 substituents (Fig. 1.20). This mass-tagged ligands were used to 
generate Ru-complexes which catalytic activity towards olefin metathesis reactions was tested 
giving slightly superior results comparing to their smaller analogues and moreover could be 
efficiently recovered from a reaction mixture by a single nanofiltration. Whereas catalytic 
activity of Pd-complexes with general formula (NHC)Pd(allyl)Cl and (NHC)Pd(cinnamyl)Cl 
were tested in the Suzuki-Miyaura coupling and Buchwald-Hartwig amination. Solvent-
resistant nanofiltration enabled to obtain Pd recovery up to 99.9% in a double-filtration 
experiment.
108
 
 
Fig. 1.20 Enlarged imidazolinium salts containing –CH2NCy2 substituents. 
 
Other sterically demanding imidazolinium salts with enlarged N-substituents or enlarged 
substituents within the N-heterocycle were reported more recently.
109,110
 Ru-complexes 
containing this enlarged ligands were tested for Ring Closing Metathesis, RCM, and Cross 
Metathesis, CM, reactions. 
 
Fig. 1.21 NHC salts: a) with enlarged substituents within heterocycle and b) with enlarged  
N-substituents. 
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Attempts to obtain functionalized pincer systems of the type PCP and NCN wherein 
the central carbon donor is a saturated NHC ligand were undertaken. Fryzuk et al.
111
 reported 
the synthesis of imidazolinium diphosphine ([PCP]H)PF6 followed by reaction with group  
10 M(0) reagents giving Ni, Pd, Pt hydride complexes [(PCP)MH]PF6. Moreover most 
recently Thomas et al.
112
 reported that NHC-ligated metal-hydride species are obtained  
if the halide-free imidazolinium salt is used but the imidazolinium C-H bond remains intact 
when imidazolinium chlorides are used. Yiğit et al.113 described synthesis of picolyl 
substituted imidazolinium hexafluorophosphate salts and their use in Pd-catalyzed Heck 
reaction of aryl bromides with styrene, whereas Le Roux
114 reported synthesis of tridentate 
NCN chelating NHC zinc complexes. 
 
Fig. 1.21 Examples of PCP and NCN pincer systems containing saturated NHC. 
 
Titanium complexes bearing a tridentate bis-phenolate-N-heterocyclic carbene dianionic 
ligands tested in controlled ring-opening polymerization reaction, of rac-Lactide115 were 
reported and functionalized azolin-2-ylidene Pd-complexes were also described.
116
 
Biscarbene Ru- and Rh-complexes
117
 and mono-, bis-, and tris-piperidine fused 
imidazolinium salts
118
 have also been developed and described. 
29 
 
Fig. 1.22 a) Biscarbene xylyl linked imidazolinium salt, b) trisipiperidine fused imidazolinium salt. 
 
Moreover bisimidazolindiylidenes ligands and tetracyclic bisimidazolindiylidenes ligands and 
their diiridium and dipalladium complexes which catalytic activity toward acylation reaction 
of aryl halides with hydrocinnamaldehyde were tested
119
 or imidazolinium salts bearing  
a long spacer coordinated to Ru-complexes used as catalyst in olefin metathesis reactions 
were reported most recently
120
. 
 
Scheme 1.10 Synthesis of tetracyclic bis(imidazolinium) salt and its dipalladium complex. 
 
This short overview shows different classes of imidazolinium salts that have been 
developed, synthesized and reported so far. Most of them were coordinated to the metal center 
giving metal-complexes that could serve as useful catalyst for several reactions among which 
C-C coupling reactions are the most abundant. The structure modification could alter  
the coordination behavior of these ligands and thereby provide the opportunity for catalysts 
fine tuning. 
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1.4.2 Chiral imidazolinium salts 
 
The field of imidazolinium salts as NHC ligands precursors was expanded likewise  
to other types of auxiliary ligands for their chiral analogs since the chiral ligand could serve  
as useful chirality center within metal complex and therefore induce stereoselectivity. 
Saturated NHC ligands could possess stereogenic centers in C4 and C5 position  
on the backbone, on the nitrogen substituents or could be a combination of both of them. 
 
Fig. 1.23 Possible stereogenic centers within chiral saturated NHCs. 
 
In this chapter the chiral imidazolinium salts will be divided into three groups depending  
on the denticity of a single ligand. 
 
1.4.2.1  Monodentate imidazolinium salts 
 
Synthesis of saturated NHC ligands possessing stereogenic centers in the imidazole ring 
(endocyclic chirality) or in the wingtip groups (exocyclic chirality) is based on a few synthetic 
protocols partially described in preceding chapters.  
The commercially available (1R,2R)-1,2-diaminocyclohexane and (1R,2R)-
diphenylethylenediamine
121
 or chiral amines 
34,122
  were applied to obtain  imidazolinium salts at 
first. 
 
Scheme 1.11 Synthesis of chiral saturated NHC precursors starting from chiral diamines.
121 
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Fig. 1.24 Saturated NHC ligands from (-)-isopinocamphenylamine, (+)-bornylamine and 
phenethylamine.
34,122
 
 
Synthesis of hindered N-aryl diamines using method presented in Scheme 1.11 
appeared to be inefficient therefore an alternative method using reductive dimerization  
of a Schiff base by a base metal in the presence of trifluoroacetic acid giving a mixture  
of diastereoisomers was introduced (Scheme 1.12).
123
 
 
Scheme 1.12 Synthesis of bulky chiral 1,2-diamines  using reductive dimerization. 
 
More recently a range of symmetric imidazolinium salts with different N-substituents starting 
from (1R,2R)-cyclohexane-1,2-diammonium mono-(+)-tartrate were prepared. Their 
reactivity and asymmetric induction as catalyst for the asymmetric synthesis of β-lactams was 
tested and evaluated.
124
 
Preparation of chiral imidazolinium salts bearing tert-butyl groups on the backbone 
was also investigated. First attempt was performed by Pytkowicz et al
125
 by oxidation  
of the (R,R)-4,5-di-tert-butylimidazoline in the presence of palladium hydroxide and 
ammonium formate. Using of (1R,2R)-di-tert-butyl ethylenediamine to obtain unsymmetric 
chiral imidazolinium salt was reported by Fournier et al.
126
 A different approach was provided 
by Zinner et al.
127 who synthesized enantiomerically pure imidazolinium salts starting from 
corresponding diimine. Chirality was introduced using a Grignard reagent followed by chiral 
resolution of the racemic mixture as the diamine tartrate and their final liberation with NaOH 
(Scheme 1.13 a). 
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Synthesis of racemic imidazolinium salts with tert-butyl substituents in the heterocyclic 
backbone obtained by the addition of tert-butyl lithium on symmetrical 1,2-bisimines was 
reported most recently however the resolution of racemic solution was unsuccessful  
(Scheme 1.13 b).
128
 
 
Scheme 1.13 Synthesis of chiral 1,2-diamines and imidazolinium salts with tBu substituents  
in the heterocycle. 
 
N-Heterocyclic carbene ligands with syn and anti methyl groups on the backbone were also 
reported and the catalytic performance of their ruthenium complexes has been evaluated 
towards metathesis reactions.
129
  
Another interesting example of acyclic 1,2-diamine used for synthesis of imidazolinium salts 
is shown in Scheme 1.14.
130
 Asymmetric induction of this and other NHCs derived from 
acyclic 1,2-diamines were tested for asymmetric synthesis of β-lactams.131 
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Scheme 1.14 Synthesis of imidazolinium salts from acyclic 1,2-diamine. 
 
Using of enantiopure chiral diamines led to NHC ligands with chiral centers in C4 and 
C5 position but saturated carbenes that have only one stereogenic center in the backbone were 
also developed. First report regarding the synthesis of such imidazolinium salts was published 
in 2003 by Hahn et al.
132
 who presented an easy synthetic approach to unsymmetrically 
substituted saturated NHC using secondary amines as starting material. The product was 
usually a racemate. 
 
Scheme 1.15 Synthesis of chiral NHC with one asymmetric center in the backbone. 
 
Synthesis utilizing an enantiomerically pure chiral diamine derived from L-proline, a naturally 
occurring amino acid was described later. The synthetic protocol is shown in Scheme 1.16. Its 
palladium complexes were tested for cross-coupling reactions.
133
 
 
Scheme 1.16 Synthesis of imidazolinium chloride from a L-proline derived diamine. 
 
Another amino acid, L-valine, was used as starting material for synthesis of chiral 
imidazolinium salts (Scheme 1.17) and theirs ruthenium complexes were tested for 
asymmetric metathesis reactions.
134
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Scheme 1.17 Synthesis of chiral imidazolinium salts starting from L-valine. 
 
More straightforward access to backbone substituted chiral imidazolinium salts from  
the reaction of formamidines with (R)-styrene oxide was also presented and is shown 
below.
135
 
 
Scheme 1.18 Synthesis of chiral imidazolinium salts from N-N’-diarylformamidines. 
 
Combination of both endocyclic and exocyclic chirality within saturated NHC 
precursors is also possible using synthetic protocols showed previously. Two examples are 
shown below. 
 
Fig. 1. 25 Imidazolinium salts with endocyclic and exocyclic chirality. 
35 
Imidazolinium salts possessing only exocyclic chirality have also been reported. 
Among them synthetic protocols for synthesis of salts containing planar chiral 
[2.2]paracyclophane,
69
 chiral 2,5-dimethylpyrrolidine,
136
 L-proline, L-phenylaniline,
137
 
carbohydrate,
138
 chiral ortho-substituted α-alkylbenzylamines139 moieties as N-substituents  
were described (Fig. 1.26 a-d). Chiral concave imidazolinium salts with axial chirality have 
also been developed.
140
 
 
Fig. 1.26 Imidazolinium salts with chiral substituents derived from: a) pyrrolidine, b) L-proline, c) L-
phenylalanine and d) ortho-substituted α-alkylbenzylamine moieties.  
 
Chiral N-heterocyclic carbene ligand system can also be assembled using  
2,2’-bipiperidine, biisoquinoline or 2,2’-bisquinoline templates.65,141 Examples are shown 
below. 
 
Fig. 1.27 Saturated NHCs with biisoquinoline and bisquinoline skeleton. 
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1.4.2.2  Bidentate imidazolinium salts 
 
Further parallel investigation of the N-heterocyclic carbene field has resulted  
in the synthesis of chiral bidentate NHC ligands. Preference for a bidentate imidazolinylidene 
was based on the hypothesis that such a ligand would induce chirality more effectively  
than a monodentate ligand.
121a 
In 2002 Hoveyda et al.
63,142
 described chiral bidentate NHC 
precursor based on an symmetric aminohydroxybinaphtalene that was first used to form its 
chiral ruthenium complex for asymmetric olefin metathesis or efficient Cu-catalyzed 
enantioselective allylic alkylations. The same group use later the biphenyl scaffold that 
occurred to be sufficient for axial chirality and combined it with additional endocyclic 
chirality to obtain chiral Ag-based NHC complex.
143
 They continued their research in this 
area and reported more recently sulfonate containing NHC ligands with stereogenic centers  
on C4 and/or C5 positions. They served as ligand for Ag-based complexes and were used and 
tested in Ru-catalyzed asymmetric metathesis reaction and Cu-catalyzed allylic alkylation for 
total synthesis of natural products.
144
 Other chiral 4-substituted imidazolinium salts bearing 
sulfonates obtained from Boc-protected amino alkohols and theirs use in γ-selective reactions 
of allylic halides with Grignard reagents were described in 2012 by Simon Woodward.
145
  
The synthesis of enantiopure unsymmetrical N-heterocyclic based zwitterions incorporating 
imidazolinium and alkylsulfonate or sulfamate groups proved to be versatile chiral solvating 
agents was also reported.
146
 Fig. 1.28 summarizes chiral imidazolinium salts described above. 
 
Fig. 1.28 Examples of chiral bidentate  imidazolinium salts. 
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Arnold et al.
147 isolated and reported the first chiral chelating alkoxy-imidazolium salts 
obtained in an one-pot reaction of two equivalents of N-tert-butylimidazole with  
2-chloromethyl-2-phenyloxirane in 2001 (Scheme 1.19 a). Seven years later they described 
the synthesis of their saturated analogues (Scheme 1.19 b). Protonolysis chemistry with 
yttrium and uranyl amido complexes have afforded the first early transition metal, and the 
first f-block saturated carbene complexes.
148
 
 
Scheme 1.19 Synthesis of: a) chiral chelating alkoxy-imidazolium salts and b) its saturated analogue. 
 
A series of chelating achiral NHC ligands that feature a chelating phenolic unit 
coordinated to Pd-complexes were described by Grubbs in 2004.
149
 But yet the first synthesis 
of chiral alkoxy-imidazolinium salts that were derived from L-valine in a six step procedure 
were reported in 2004. These salts have been used as chiral derivatizing agents  
for ee determination of chiral carboxylate.
150
 The same group decided to evaluate the potential 
of this salts as new chelating alkoxy-NHC ligands in the enantioselective Cu-conjugate 
addition of diethylzinc to cyclohexenone or Cu-catalyzed asymmetric conjugate addition  
of Grignard reagents to trisubstituted enones to form all-carbon quarternary chiral centers. 
They have extended this new class of imidazolinium salts through synthesis of 20 other salts 
derivatives easily accessible from commercially available β-aminoalcohols and various 
substituted anilines or alkylamines.
151
 They continued research in the area of this class  
of imidazolinium salts tested in the above mentioned transformations and have more recently 
reported several additional alkoxy-chelating derivatives possessing the stereogenic center  
38 
in the heterocyclic ring or in chelating side chain starting from amino acids with various  
N-substituents.
152
 
 
Scheme 1.20 Synthesis of alkoxy-imidazolinium salts with stereogenic center in a) chelating side 
chain or b) within the heterocycle. 
 
Moreover simple chiral bidentate NHC ligands that carry an achiral coordinating 
group as N-substituent and possess two stereogenic centers within the heterocycle obtained  
in three-step procedure were described by Katsuki.
153
 They serve as efficient chiral auxiliaries 
for the Cu-catalyzed asymmetric conjugate addition of dialkylzinc to acyclic enones. 
 
Fig. 1.29 Examples of alkoxy- and phenyloxy-imidazolinium salts. 
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The alkoxy bidentate NHC ligands are not the only example of this class of saturated 
NHC ligands. Phosphine-, thiolate-, mesylate-, tosylate- and picolyl-containing NHC ligands 
have also been reported. Mauduit`s group
154
 introduced the second chelating function  
by converting the hydroxyl group into a leaving group such as tosylate and mesylate. Sulfur 
and phosphine function were introduced by nucleophilic substitution of the mesylate leaving 
group by using sodium thiolate and potassium diphenylphosphide, respectively  
(Scheme 1.21). These ligands have been evaluated in the enantioselective Cu-catalyzed 
conjugate addition to cyclic and acyclic enones displaying good catalytic activity. 
 
Scheme 1.21 Synthesis of sulfur and phosphine functionalized NHCs. 
 
Pfaltz et al.
155
 on the other hand prepared phosphine- and phosphinooxy-substituted 
NHC ligands and theirs iridium complexes that were tested in Ir-catalyzed hydrogenation. 
Palladium complexes containing picolyl functionalized NHC ligands with different 
substituents were synthesized and tested for the Mizoroki-Heck reaction giving good 
conversion and regioselectivity.
156
 Chiral bidentate NHC-thiolate ligands derived from 
levamisole were also reported. Their palladium complexes and triruthenium and triosmium 
carbonyl clusters were described.
157
 Most recently chiral imidazolinium salts functionalized 
with urea-type hydrogen-bond donor moieties were prepared and their NHCs were evaluated 
as organocatalysts in enantioselective homoenolate additionreactions.
158
 Examples of above 
mentioned NHC precursors are shown in Fig. 1.30. 
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Fig. 1.30 NHC precursors with sulfur and nitrogen function: a) picolyl N-substituent, b) methyl 
levamisolium triflate, c) hydrogen-bond-donor-functionalized imidazolinium salt. 
 
 
1.4.2.3  Tridentate imidazolinium salts 
 
Angelici et al.
159 used (1R,2R)-diaminodiphenylethylenediamine and (1R,2R)-
diaminocyclohehane as building block for first chiral tridentate diquinolyl-imidazolinium salt 
and its copper-complex (Scheme 1.22). 
 
Scheme 1.22 Synthesis of diquinolyl-imidazolinium salt. 
 
Simultanously imidazolinium salts incorporating two chiral hydroxy groups on their 
N-substituents were introduced by Wilhelm et al.
160
 who prepared appropriate bis(amino 
alcohol) from amino alcohols and 1,2-dibromoethane or chiral diamines and then used triethyl 
orthoformate to close the ring. These ligands in combination with different metallic salts were 
investigated in the diethylzinc addition to aldehydes with good yields and enantioselectivity. 
Using similar procedure Zhengning et al.
161 synthesized imidazolinium salts containing two 
N-functionalized hydroxyl or alkoxyl groups that were applied to catalyze the asymmetric 
conjugate addition of diethylzinc to cyclohex-2-enone. 
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Fig. 1.31 Chiral symmetric NHC containing two N-functionalized hydroxyl or alkoxyl group. 
 
The successful use of enantiomerically pure tridentate NHCs as chiral modifiers was reported 
in 2010.
162
 Formation of a heterogeneous catalyst from Fe2O3/Pd nanoparticles and chiral 
tridentate imidazolinium salts enable creation of a catalytically active entities tested for 
asymmetric α-arylation reactions. Moreover this catalyst system is easy to remove and recycle 
without loss of activity and selectivity. 
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Part 2 
 
2. Results and discussion 
 
2.1 Introduction  
 
Over the past two decades, great achievements were made in catalysis using NHCs  
as ligands. NHC ligands combined with metal pre-catalysts exhibit high activities in various 
important organic transformations including Pd-catalyzed cross-coupling reactions
163
  
and Ru-catalyzed metathesis reactions
164
 or Rh-catalyzed hydrosilylation reactions
165
. A wide 
range of NHC ligands are now commercially available. The design of chiral NHCs for use 
in stereoselective catalytic transformations has been destined to provide an additional 
dimension to the field. Synthesis of new chiral NHC catalysts is supported  
by the development of new synthetic routes to chiral NHC ligands and their metal 
complexes.
41
 Strategies have been explored that contain symmetrical or unsymmetrical, 
mono-, di- or tridentate NHCs with chirality within the backbone or on the N-substituents, 
which is described in the literature part of this work.  
Considering, that even a minor change in the ligand sphere of the catalyst can 
significantly alter its stability, reactivity or selectivity, and thus enhance or reduce its 
efficiency, we developed in our group a new strategy of forming chiral, bidentate NHC 
ligands. Herein, we report the synthesis of chiral imidazolinium salts derived from 
commercially available enantiopure amino acids and attempts to obtain their late transition 
metal complexes. 
 
 
 
 
 
43 
2.2 Development of chiral, unsymmetrical imidazolylidene ligands 
starting from amino acids 
 
The new synthetic route is proposed here to obtain chiral, bidentate imidazolinium salts 
that could serve as comfortable NHC ligands for late transition metal (Ru, Pd, Rh) complexes.  
The procedure for the synthesis of imidazolinium salts 5 as a five membered (amino)(amido) 
NHC ligand from enantiopure Boc-protected L-alanine as shown in Scheme 2.1 was initially 
attempted.  
 
 
Scheme 2.1 The synthetic path for (amino)(amido)NHC precursors. 
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Treatment of Boc-protected L-alanine (the same procedure for D form) with 2,4,6- 
trimethylaniline in the presence of dicyclohexylcarbodiimide (DCC) in THF provided  
a product 1 in very good yield. Afterward the amine deprotection with 2M HCl solution  
in diethyl ether resulted in the 2-amino-N-mesitylpropanamide hydrochloride, 2. Subsequent 
reaction with 2-hydroxybenzaldehyde or 3,5-di-tert-butyl-2-hydroxybenzaldehyde in MeOH 
in the presence of MeONa led to Schiff bases 3a and 3b, respectively. 
The compounds were identified by the 
1
H NMR spectroscopy. Thus the formation of Schiff 
bases was confirmed by presence of -CH=N- resonances at δ=8.51 ppm for both; 3a and 3b 
derivatives (in CDCl3). Overall yield after these 3 steps was 63%. Characteristic feature of all 
above mentioned derivatives in 
1
H NMR spectra is the presence of resonance signals  
of the methyl group attached to the chiral carbon as a doublet at ca 1.6 ppm and a methine 
proton at the chiral carbon as a quartet at ca 4.2 ppm vicinally coupled with J~7 Hz. 
Reduction of 3a and 3b with NaBH4, followed by addition of HCl afforded 
(amino)(amido) hydrochloride derivatives 4a and 4b. Vicinally coupled resonances from the 
methyl group protons and hydrogen attached to the chiral carbon were observed at 1.7 ppm 
(doublet) and at 4.3 ppm (multiplet). 
The last step, i.e. reaction of 4a and 4b with triethyl orthoformate that aimed at  
the corresponding imidazolinium chloride salts: 5a and 5b led after chromatographic workup 
into hydrolized species of the mass enlarged by one oxygen atom in comparison with that of 
5a as identified by mass spectrum (Fig. 2.1). After incorporation of carbon atom into 4a at 
least three possible intermediates which can be formed (Scheme 2.2). Eventually, only two of 
them can lead to the final compound 6.  
The NMR spectra of 6 are composed of two sets of resonances. The mixture  
of products in the molar ratio 1.0 : 0.8 was repeatedly isolated from the reaction mixture. Its 
1
H NMR spectrum in DMSO-d6 is shown below (Fig. 2.2 c). There are 6 resonances in the 
region 8.2-9.9 ppm in the 
1
H NMR spectrum in dmso-d6 (Fig. 2.2 c). Four of those disappear 
upon addition of deuterium oxide in situ (Fig. 2.2 b). Upon addition of KOH to the starting 
compound the same resonances disappear and additionally all proton resonances shift 
remarkably upfield (Fig. 2.2 a).  
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Figure 2.1 Mass spectrum of 6 - the product of ring closing reaction of 4a.  
 
 
Scheme 2.2. The possible products of reaction of 4a with triethylortoformate. 
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Figure 2.2 The 
1
H NMR spectra in dmso-d6 for a) mixture after addition of KOH in H2O, b) mixture 
after addition of D2O, c) mixture of two products 6. 
 
The spectral characteristic feature of imidazolidine salts, like 5, is the presence of: -N-CH-N- 
proton resonance at ca 8-9 ppm and coupled resonances of CH3- group and hydrogen attached 
to chiral carbon at ca 1.7 (doublet) and in the 3.5-4.5 region (quartet), respectively. The 
methylene diastereotopic protons of this moieties should give characteristic resonance signal 
pattern in 
1
H NMR spectra as two separate doublets with geminal coupling constant, J~14 Hz. 
Almost all of the proton and carbon resonances of 6 were doubled so that in both 
1
H 
and 
13
C NMR two sets of similar resonances were observed, what could indicate the presence 
of two isomers. Characteristic resonance signals in 
1
H NMR around 8.2-8.5 ppm assigned to -
N-CH-N- proton (initially considered as originated from imidazolidine moiety) were 
observed. Moreover characteristic resonance signals of diastereotopic methylene group proton 
resonances in the region 4.35-4.73 ppm occur as two pairs of dublets with coupling constant 
J=14 Hz and the methine proton of the chiral carbon at 4.27 ppm (second one at 4.85 ppm) 
coupled with methyl group protons at 1.65 (second one at 1.55 ppm) indicated the presence of -
Ar-CH2-N-CH(CH3)-CO- fragment.  
Two isomers remained at the same molar ratio in every synthetic attempt, suggesting the two 
compounds were rotational isomers. Therefore I have performed the variable-temperature 
1
H 
NMR measurements of the mixture in DMSO-d6. Fig. 2.3 demonstrates two relevant fragments of 
spectra (4.2-4.7 ppm and 2.4-1.1 ppm) recorded at 25 ºC, 45 ºC, 75 ºC, 100 ºC, 125 ºC, 150 ºC.  
a 
b 
c 
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Fig. 2.3 Temperature dependent 
1
H NMR spectra of mixture 6:6’ 1.0:0.8 in DMSO-d6. 
 
The coalescence point was observed at 373 K, indicating that 6 and 6’ are interexchangable 
isomers.  
Considering the NMR spectra and final formula of the compounds 6 the probable route and 
structure of the product can be that showed at scheme 2.3. Thus, 6 can be considered as 
product of hydrolysis of unstable intermediates B or C (presented at scheme 2.2). Within this 
product 6, the protonation-deprotonation intramolecular equilibrium probably takes place. 
Namely, the compound can be considered as zwitter-ionic tautomer, because the carboxyl 
group has pKa ca 5, while aminidium group proton pKa is much larger. Nonetheless, the 
cross-peak in HMBC spectrum indicates that even temporary attachment of this proton into 
carboxylic carbon takes place. The presence of two isomers, probably cis-trans around 
amidinium C=N bond might lead to doubled NMR spectra of 6. 
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Scheme 2.3. The structure of side-product 6 on the basis of mass and NMR spectra. The arrows 
indicate the magnetization transfer from neighboring hydrogen into carboxylic carbon 
in HMBC experiment. 
 
The attempts to obtain similar (amino)(amido)NHC ligands or bis(amido)NHC ligands 
were undertaken in our laboratory and described in the doctoral thesis of Allaert (Fig. 2.4).
166a 
The NHC ligands were successfully obtained in case of NHC precursors A and C and failed 
or were not reproducible for the imidazolinium salt B. Only cationic ligand of A salt was 
introduced as carbene ligand into Ru complex. 
 
Fig. 2.4 (Amino)(amido)NHC precursors. 
 
Presumably the difficulties in obtaining this class of NHC precursors or corresponding 
carbenes were caused by the presence of α-carbonyl protons in B or insufficient stabilization 
of the carbene through mesomere donation of the substituents.
166a
  
Considering the starting enantiomerically pure alanine, the another issue which might lead to 
loss of chirality on α-carbon was enolization reaction in compound 5, if isolated. The 
racemization might involve the enol form, which was in fact isolated and characterized by 
Benhamou et al for imidazole-2-ylidene-4-olate.
166b-c
 
 
On the basis of above mentioned experiences and due to inconvenience of the last step  
of synthetic route presented at Scheme 2.1 I have modified the synthetic route to obtain NHC 
49 
ligands. I have replaced the selective reducing agent NaBH4 with stronger BH3
.
THF complex. That 
caused the reduction of both -C=O bond to –CH2- and -CH=N- bond to -CH2-NH- affording 
diamine hydrochlorides 7a and 7b. After reaction with triethyl ortoformate the desired 
imidazolinium salts 8a and 8b were obtained at good total yield (Scheme 2.4). 
 
Scheme 2.4 Synthetic path of imidazolinium salts 8a and 8b. 
 
Using this route four imidazolinium salts starting from Boc-L-alanine (8a, 8b) and Boc-D-
alanine (8c, 8d), which formulae are shown in Fig. 2.5, were obtained.  
Identity of the final imidazolinium salts were confirmed by NMR, IR, MS spectra and 
elementary analysis. The assignment of resonances of all obtained products in the 
1
H and  
13
C NMR spectra was performed using 1D and 2D homonuclear COSY and heteronuclear 
HSQC and HMBC experiments. 
The expected feature of the 
1
H NMR spectrum is related to the chiral imidazolydine carbon 
originated from enantiopure substrate: L- or D-alanine. Thus methylene protons of N-benzyl 
groups as well as those attached to imidazolydine carbon next to chiral center, should be 
diastereotopic, while the resonance of hydrogen attached to chiral carbon should be multiplet. 
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Fig. 2.5 Hydroxybenzyl imidazolinium salts obtained from enantiopure L- and D-Boc-alanine. 
 
Indeed, the benzyl methylene protons show high magnetic non-equivalence; the chemical 
shift difference between them is 0.27 ppm in 8a and 8c and 0.35 ppm in 8b and 8d 
compounds, and they are geminally coupled with J=14 Hz. Even larger chemical shift 
difference between ring methylene protons was observed, which in all cases was larger than 
0.50 ppm. This is obvious because they are vicinal to methyl group and hydrogen atom 
attached to center of chirality, while benzyl methylene hydrogen atoms are one bond further 
from substituents at chiral carbon. The diagnostic for imidazolydine ring in 8 is the singlet 
resonance of –N-CH=N- ring proton, which appears at 8.90-9.00 depending on N-substituent.  
The total 
1
H and 
13
C resonance assignment of salts 8a and 8b shown in Fig. 2.5, is collected in 
Table 3.1 in the experimental part. The 
1
H NMR spectra of salts 8 are slightly concentration 
dependent presumably due to dissociation of salts 8. Thus, the spectra of 8a and 8c which 
were recorded at different concentrations, showed distinct chemical shifts. In order  
to confirm, that compounds 8a and 8c are indeed the enantiomers, the additional 
1
H NMR  
experiment has been performed; the spectra of separate solutions of 8a and 8c were recorded, 
and then these solutions were mixed and the 
1
H NMR spectrum was recorded. The spectrum 
of equimolar mixture of 8a and 8c was composed of one set of resonances. 
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Using analogue procedure I have prepared the imidazolinium salt starting from  
Boc-L-phenylalanine (Scheme 2.5). Products 9, 10, 11 were obtained using above described 
procedure and isolated at good yield. Directly after reduction of product 11 with BH3
.
THF 
complex that afforded hydrochloride 12, the  reaction with triethyl ortoformate was performed 
to obtain ring closed product 13 with moderate yield. Its identity was confirmed by NMR and 
MS analysis. Hydrochloride 12 was not isolated from reaction mixture. 
 
Scheme 2.5 Synthetic approach of product 13. 
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Similarly the benzyl methylene protons show high magnetic non-equivalence; the chemical 
shift difference between them is 0.28 ppm and they are geminally coupled with J=14.5 Hz. 
Even a higher chemical shift difference between ring methylene protons was observed and 
equal to 0.41 ppm. On the other hand the shift difference between benzyl methylene protons 
attached to center of chirality was barely 0.06 ppm. The diagnostic for imidazolydine ring  
in 13 is the singlet resonance of –N-CH=N- ring proton, which appears at 8.97 ppm. The total 
1
H and 
13
C resonance assignment of salt 13 shown in Scheme 2.4 is collected in Table 3.1  
in the experimental section. 
As by-product imidazolinium salt 14 was isolated from the reaction mixture. However its 
mass and NMR spectra did not allow to conclude about its identity.  
 Because the problem of enolization on carbon-4 during the reduction step executed 
with BH3, step 3  7 (Scheme 2.3), remained real danger to preserve enantiomeric purity in 
final products 8 and 13, the final products 8a-d were checked by polarimetry or CD 
spectroscopy. I have found that pair of 8b and 8d compounds showed opposite specific 
rotation of -1.1  0.1 and +1.3  0.1{[𝛼𝐷
20] = −1.1 (2, 𝑀𝑒𝑂𝐻), [𝛼𝐷
20] = +1.3 (2, 𝑀𝑒𝑂𝐻)}. 
Although the specific rotation of 8a and 8c was too low to measure by polarimeter, the CD 
spectrum of 8a showed, that compound was not racemate; two Cotton effects: the positive at 
280 nm (+0.6) and negative at 255 nm (-0.25) were observed. For compound 13, derived from 
L-phenylalanine, the specific rotation was much larger than for all compounds 8, namely 
[𝛼]𝐷
20 = + 44.7. 
With salts 8 and 13 in hand I decided to coordinate them to Ru-, Rh- and Pd-
complexes to examine theirs behavior and utility as auxiliary ligands for this late transition 
metals. We thought they could serve as a useful chiral bidentate NHC ligands for metathesis 
reactions or C-C or C-N coupling reactions. 
 
 
2.3 Synthesis of metal complexes 
 
Transition metal complexes of NHC can be obtained using four methods:  
a) reaction of a transition metal complex with a free carbene ligand that is preformed  
or generated in situ,  
b) reaction of an imidazolium salt with a transition metal complex containing a basic 
ligand, like alcoholates, 
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c) transmetallation from a Ag-NHC complex,  
d) reaction of an azolium salt with transition metal salt in the presence of a weak base. 
I have tested methods a and b in order to coordinate imidazolinium salt 8a or carbene derived 
from 8a to selected Ru, Rh and Pd complexes what will be further described. 
 
 
2.3.1 Coordination of 8a to ruthenium(II) 
 
The NHC-Ru complexes are known as useful and efficient metathesis reaction 
catalysts.
164,167
 
Imidazolydinium cations undergo readily deprotonation upon various agents, like sodium 
hydride, alcoholates, or LiHMDS to generate carbene. The latter coordinates to ruthenium. 
Many Ru-NHC complexes are known, including those containing chiral NHC. Such ligands 
provide a chiral environment around the metal center and therefore might be useful to induce 
enantioselectivity in catalyzed reactions.
164  
For synthetic purposes it seemed convenient to 
use ruthenium-phosphine complexes, because bulky phosphine ligands like 
tris(cyclohexylphosphine) (PCy3) or triphenylphosphine (PPh3) serve as readily leaving 
ligands.  
I aimed at obtaining the ternary ruthenium complexes containing two carbon 
coordinated ligands. Bis(tricyclohexylphosphine)benzylidine ruthenium(II) dichloride  
(1
st
 generation Grubbs catalyst, 15) and bis(tricyclohexylphosphine)-3-phenyl-1H-inden-1-
ylideneruthenium(II) dichloride (Neolyst (M1), 16) were used as starting ruthenium 
substrate.
168 
I considered that such complexes could serve as useful metathesis reaction 
catalyst and they will complement this big Ru-NHC complexes family. 
 
Fig. 2.6 Ru-complexes used as starting materials. 
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At first I have decided to perform the reaction of 8a and 15 in presence of strong base 
KHMDS in toluene in a NMR tube with external lock with CDCl3 and I monitored  
the progress of reaction using 
31
P NMR measurements. The spectra recorded after 1, 2, 4, 6, 
and 22 hours are shown in Fig. 2.9 below. After first few hours, resonance signal of complex 
15 at 37 ppm was decreasing and resonance signal of tricyclohexylphosphine (PCy3)  
at 11 ppm was increasing. This could indicate that phosphine ligand is leaving and exchanged 
by in situ generated carbene. After 22 hours complex 15 was completely consumed whereas  
at 46 ppm resonance signal of new complex containing at least one PCy3 group was observed. 
 
Fig. 2.7 
31
P NMR spectra of reaction of 8a and 15 with KHMDS in toluene with CDCl3 as external 
standard after 1, 2, 4, 6 and 22 hours (from bottom to top, respectively). 
 
 
Careful examination of reaction mixture, which showed the presence of new weak intensity 
resonance signal in 
31
P NMR suggested the formation of an intermediate form containing 
PCy3 moiety in ternary Ru complex 17. 
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Fig. 2.8 Probable structures of complex. 
 
The same experiment was performed using 8b as auxiliary ligand. Similar results were 
observed and the new 
31
P NMR resonance signal from a new complex appeared  
at 47 ppm. However intensity of this signal was very weak. 
 
The reaction of 8a and 15 with KHMDS at the same conditions was monitored  
by 
31
P NMR in CDCl3 and resulting spectra are shown in Fig. 2.11 below. The resonance 
signal of starting product 15 was observed at 36 ppm and the resonance signal of free PCy3 
was observed at 11 ppm likewise in experiment shown above (Fig. 2.9) but any new signal 
was observed at ~46 ppm. Strong resonance signal assigned to tricyclohexylphosphine oxide 
(PCy3O) at 51 ppm was observed instead. Since the first experiment was performed in NMR 
tube without protection against air and moisture and in the second experiment samples were 
taken, dried and redissolved in CDCl3. Most probably only the complex 17 was formed and 
the intermediate form was not observed.  
Encouraged by NMR sample scale experiments I tried to isolate product 17 from the reaction 
mixture. The first attempts gave promising result and I were able to isolate product containing 
NHC moiety. Presence of resonance signals between 4.7 and 3.2 ppm, characteristic for 
ligands 8 moiety, that were shifted in comparison with those of starting ligand 8a in the same 
conditions, indicated the formation of a new product (this spectrum is shown in Fig. 2.10). 
Upfield coordination shift ~0.40 ppm for the diastereotopic methylene protons of N-benzyl 
groups as well as those attached to imidazolydine carbon next to chiral center and  methine 
proton at chiral center were striking. But the lack of characteristic downfield signal at ca 19 
ppm from the Ru=CH-Ph proton in 
1
H NMR and ambiguous resonances in the aromatic 
region evidenced that the benzylidene moiety was missing in the product. In the 
31
P NMR 
spectrum only single resonance signal at 51 ppm from the PCy3O was observed. The obtained 
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quantity of product was insufficient for a full analysis and all further attempts to reproduce 
this reaction performed in the same conditions failed. 
 
Fig. 2.9 
31
P NMR spectra of reaction of 8a and 15 with KHMDS in CDCl3 after 1, 2, 4, 6 and 22 hours 
(from bottom to top, respectively). 
 
 
Fig. 2.10 The 
1
H NMR spectrum of product isolated from reaction of 8a with 15 in CDCl3. 
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Therefore, I have changed the starting material to a relatively cheaper RuCl2(PPh3)3 
(18) complex in order to check if ligand 8a would coordinate and isolation of its probable 
product (shown in Scheme 2.6) would be successful.  
 
Scheme 2.6 Coordination of ligand 8a to Ru-complex 18.  
 
I have performed the series of experiments using THF or toluene as solvents and 
different bases such us: KHMDS, tBuOK, NaH, K2CO3. Coordination of ligand 8a with 
complex 18 in presence of KHMDS or NaH did not occur. Purification of the reaction 
mixtures using flash column chromatography or crystallization did not allow to separate any 
of expected products. 
The reaction of 8a with complex 18 in the presence of tBuOK or K2CO3 in the 1:1:2 
molar ratio in THF led to a mixture of new products. Presence of characteristic resonance 
signals from ligand 8a in the 
1
H NMR spectra and appearance of new resonance signals  
in 
31
P NMR spectra indicated formation of new Ru-NHC complexes. On Figure 2.11  
31
P NMR spectra of isolated mixtures are compared. 
 
Fig. 2.11 
31
P NMR spectra of: a) starting complex 18 and products isolated in reaction with b) tBuOK 
and c) K2CO3. Spectra taken in CDCl3. 
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Several new resonance signals were observed in both cases what could indicate 
formation of complex 19, with various geometry (at least 3 isomers can be expected). 
However chromatographic separation of this mixture failed. Additionally all obtained and 
analyzed samples were contaminated both with free triphenylphosphine (PPh3) and 
triphenylphosphine oxide (PPh3O). Their resonance signal are observed in 
31
P NMR spectra at 
-4 and 29 ppm respectively. This two resonance signals alone were observed in all samples 
received from reaction of 8a and complex 18 with KHMDS and NaH. Probably the failure of 
previously described experiments was mostly caused by using the unstable starting materials, 
complex 18. 
Simultaneously, I tried to coordinate ligand 8a to a Ru-indenylidene complex 16 that 
is more stable and less moisture and air sensitive. Taking into account my earlier experiments 
and after a few preliminary experiments with various solvents and bases I have performed the 
reaction according to Scheme 2.7 and identified product 20 as follows. The 1M KHMDS 
solution in toluene was used as a base. The workup of the post-reaction mixture by column 
chromatography the first, dark red fraction was isolated. The 
1
H NMR spectrum of this crude 
fraction evidenced the presence of PCy3 moiety and 8a ligand (Figure 1.12 c). On the other 
hand the lack of resonance signals of the indenylidene moiety in the aromatic region of the 
1
H 
NMR (for the spectrum of starting complex 16 see Fig. 1.12 b) suggested formation of 
imidazolinium Ru-complex 20 without indenylidene moiety in its structure. The spectrum of 
coordinated ligand 8a showed no presence of N-CH-N resonance at 9 ppm, while all other 
resonances were shifted upfield if compare to that of free ligand (Fig. 1.12 a). Upfield 
coordination shift of ~0.40 ppm for the diastereotopic methylene protons of N-benzyl groups 
as well as those attached to imidazolydine carbon next to chiral center and methine proton at 
chiral center were observed. 
The isolated product showed also the new resonance in the 
31
P NMR spectrum, which 
did not originate from starting complex 16, nor PCy3 (Fig. 2.13).   
 
Scheme 2.7 The reaction scheme and isolated product 20. 
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Fig. 2.14 The 
1
H NMR spectra of: a) ligand 8a, b) Ru-complex 16 and c) isolated product 20,  
performed in CDCl3. 
 
 
Fig. 2.13 
31
P NMR spectra of: a) PCy3, b) Ru-complex 16 and c) isolated product 20, performed 
 in CDCl3. The resonance signal at 51 ppm belongs to PCy3O moiety. 
 
Similar procedure was applied again to obtain the complex with two ligands: 8a and 
indenylidene attached to ruthenium(II). The ligand 8a was added to starting complex 16 and 
KHMDS as 1:1:10 molar ratio mixture was kept at room temperature for 36 hours to avoid 
decomposition of target product by dissociation of any ligands except chloride or phosphine.  
Such a mild reaction conditions and separation by flash column chromatography resulted in 
isolation of the dark-red product, which showed quite complicated 
1
H NMR spectrum (Fig. 2.14 c). 
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For comparison the 
1
H NMR spectra of the mixture, probable complex 21 and starting  
Ru-complex 16 are shown in Fig. 2.14 (for clarity the range of –PCy3 resonances between 
2.0-1.0 ppm are omitted). This mixture was also subjected for MS spectrum, which showed 
the presence of two compounds numbered here as 21. (Fig. 2.15).  
In fact the mass spectrum is quite clear and indicates that two compounds are: [(8a-
H)2Ru(Ind)] and [(8a-H)2Ru(Ind)]2. The products are in equilibrium in solution as indicated 
by presence of two spectra. Therefore they can be represented by the formulae (Fig. 2.16), 
while the 
1
H NMR spectrum of this mixture is presented in Fig. 2.14 c. 
Two peaks observed in mass spectrum (Fig. 2.15) correspond to {[(8a-H)
-
]2Ru(Ind) + H
+
} 
(calculated for C55H56N4O2Ru+H
+
 907.3252, observed 907.3498) and to {[(8a-H)
-
]2Ru(Ind)}2 
+ H
+
} (calculated for C110H112N8O4Ru2+H
+
 1813.697, observed 1813.6917). Both molecular 
ion peaks reveal proper hyperfine structure related to abundant ruthenium isotopes in 
comparison with the simulated ones (
96
Ru, 5.51%;
98
Ru, 1.87%; 
99
Ru, 12.72%; 
100
Ru, 12.62%; 
101
Ru, 17.07%; 
102
Ru, 31.61%; 
104
Ru, 18.58%). 
 
Fig. 2.14 
1
H NMR spectra of: a) starting indenylidene Ru complex 16, b) isolated complex 20 and  
c) obtained complex 21, in CDCl3. 
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In the 
1
H NMR spectrum the diagnostic proton resonance of the indenylidene ligand  
is shifted 0.50 ppm downfield from 8.65 in the complex 16 to 9.15 in the complex 21. 
Moreover, the downfield resonance from salicylic OH was absent in the spectrum of 21, 
indicating the involvement of salicylate oxygen as donor atom. All attempts to crystallize 21 
from the dark-red mixture failed till now. 
According to the spectral assignments the probable formulae of mono- and di-nuclear 
ruthenium complexes can be represented as Fig. 2.6. 
 
 
 
Fig. 2.15 Mass spectrum of ruthenium complexes 21 of the general formula {[(8a-H)
-
]2Ru(Ind)}n. 
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Fig. 2.16 The formulae of the monomeric and one of many possible dimeric compounds of the 
general composition {[(8a-H)
-
]2Ru(Ind)}n, where n = 1 (monomeric pentacoordinate 
formula, left side) or n=2 (dimers). There are four possible dimeric compounds with all 
(8a-H)
-
 C,O- or O,C bridging ligands and many dimers with two C,O- or O,C- bridging 
(8a-H)
-
 ligands and two C,O chelated ligands into two ruthenium(II) centers. 
 
 
2.3.2 Coordination of 8a to rhodium(I)  
 
Rhodium(I) is a useful catalytic cation. The Rh(I) complexes containing N-
heterocyclic carbenes were developed and used as catalysts for hydrosilylation reactions
169
. 
We have explored the coordination ability of imidazolinium cation 8a to Rh(I). The 
convenient starting material to perform this chemistry is dirhodium complex 22 which is 
stable and soluble in organic solvents. 
 
Fig. 2.17 Bis(1,5-cyclooctadiene)dirhodium (I) dichloride complex. 
 
The reaction of 8a with 22 was performed in toluene or THF with tBuOK or K2CO3 as a base. 
In all cases the 
1
H NMR spectrum of isolated post-reaction mixture showed formation of two 
products. Product separation via flash column chromatography on silica gel did not lead  
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to separation and finally the mixture of products in 5:1 molar ratio was obtained  
as demonstrated by the 
1
H NMR spectrum (Fig. 2.18). 
 
Fig. 2.18 The 
1
H NMR spectrum of mixture of Rh(I) complexes in CDCl3.  
 
None of two products showed resonances from starting cyclooctadiene ligand. In basic 
condition applied in synthesis, the cation of 8a was converted into neutral molecule and 
coordinated to Rh(I). The downfield resonance from salicylic OH was absent in the spectrum 
of the products, indicating the involvement of salicylate oxygen as donor atom. Coordination 
shift was 0.93 ppm for –N-CH=N- proton and benzyl methylene protons. The largest 
coordination shift (1.34 ppm) was found for methine proton. All ligand resonance signals 
were upfield shifted.  
Moreover presence of cross peak between methine proton at 2.94 ppm and adjacent methyl 
group protons and one of the adjacent methylene protons in COSY experiment was observed 
for the more abundant form.  
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Fig. 2.19 Fragment of COSY spectrum of Rh(I) complex mixture in CDCl3. 
 
This indicates formation of complex with neutral imidazolyl ligand coordinated via O and  
C atoms rather that coordination of carbene itself. The chloride anions remained coordinated. 
Considering the geometry of two rhodium(I) centers the formation of two isomers: extended 
cis and extended trans (Fig. 2.20) are expected. These two isomers convert slowly at NMR 
time-scale, they cannot be separated, however, chromatographically. The attempts  
to crystallize this material failed. 
 
Fig. 2.20 Extended cis and extended trans isomers of Rh complexes, (23). 
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2.3.3 Coordination of 8a to palladium(II) 
 
Similarly to ruthenium(II) and rhodium(I), also the palladium(II) is inert enough  
to follow the ligation reaction and diamagnetic, which enables to characterize the reaction 
products with 
1
H NMR spectroscopy. Therefore I have tested coordination ability of 8a  
to palladium. The simple palladium dichloride salt is poorly soluble in any solvent, therefore 
the Pd(py)2Cl2 was generated in situ in pyridine or pyridine-d5 for NMR spectral monitoring 
of the reaction progress. Additionally K2CO3 was used as base in order to ensure 
deprotonation of cationic 8a. 
 
Scheme 2.8 Scheme of synthesis of NHC Pd-complex, (24). 
 
After 24 hours of stirring a 
1
H NMR spectrum of the post reaction mixture in pyridine-d5 was 
recorded (Fig. 2.21). 
 
Fig. 2.21 
1
H NMR spectrum of post reaction mixture in pyridine-d5. 
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Five doublets with different intensity in the region 2.1-1.4 ppm that are diagnostic 
resonances for methyl group protons at stereogenic center as well as a group of singlets 
between 2.3-2.1 ppm that are characteristic resonances for methyl groups protons of the 
mesityl substituents indicated the presence of at least five products.  
Likewise in previous cases we were able to isolate a fraction of isomers using flash column 
chromatography on silica gel. Also in case of square planar complexes of palladium(II)  
we obtained the mixture of two compounds. The 
1
H NMR spectrum of this mixture is shown 
in Fig. 2.22. Presence of two doublets at 1.46 ppm and 3.38 ppm diagnostic for the methyl 
group attached to chiral carbon and coupled with its methine proton. 
Since pyridine-d5 was used no resonances of pyridine ligand was observed in CDCl3. 
Therefore the synthesis was performed according to the same protocol with pyridine.  
The mixture of products was obtained.  
 
 
Fig. 2.22 The 
1
H NMR spectrum of mixture of palladium(II) isomers in CDCl3. 
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Cross peaks between two separate methine protons at 2.94 and 3.34 ppm and adjacent methyl 
group protons at 1.75, and 1.45 ppm, respectively were observed in COSY experiment while 
no cross peaks of the adjacent methylene protons were observed (Fig. 2.23). 
 
Fig. 2.23 Fragment of COSY spectrum of Pd(II) complex mixture in CDCl3. 
 
 
2.4 Modified PAMAM dendrimers  
 
Dendrimer is a particular case of polymer with multiple branches and it is made  
by successive growth of polyfunctional monomers onto an initiator with multiple 
functionality. This gives rise to a tree-like structure with the number of branches increasing 
away from a center. The spectrum of dendrimer families is now very broad and have been 
accurately described and reviewed
170
. The properties of  dendrimers were first examined with 
Tomalia’s polyamidoamine (PAMAM) dendrimers that are now commercial.171 Since our 
group was investigating this class of  dendrimers we decided to use this structures for 
immobilization of Ru-complexes on their surfaces
172
 and studied their potential catalytic 
activity as heterogeneous catalyst for olefin metathesis reactions.  
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2.4.1 Synthesis of PAMAM dendrimers 
 
Following Tomalia’s procedure173 I prepared the 3rd generation of PAMAM 
dendrimer. It was synthesized by the divergent method with ethylenediamine as a core. This 
method involved a two-step iterative sequence to produce either ester or amine terminated 
structures. Sequence is composed of (a) alkylation with methyl acrylate followed by (b) 
amidation with excess of ethylenediamine. We obtained amine terminated dendrimer with 
thirty two –NH2 groups. Shorthand designation of this structure is G3-PAMAM(-NH2)32.  
Its structure is shown in Fig. 2.24. 
 
Fig. 2.24 Structure of the 3
rd
 generation PAMAM dendrimer G3-PAMAM(-NH2)32. 
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Then I modified the terminating group via condensation of G3-PAMAM(-NH2)32 with 
salicyl aldehyde to form Schiff bases on the periphery of the dendrimer. I have obtained  
the conjugate G3-PAMAM(-NH2)32 with 50% and 100% amine groups substituted with 
salicylic residue attached via aldimine bonds (Scheme 2.9). 
The reaction was performed in MeOH using 16 and 32 salicyl aldehyde equivalents  
to obtain half- and thoroughly condensed terminal groups respectively. I determined  
the degree of conversion using 
1
H NMR spectroscopy. To estimate the degree of aldehyde 
substitution we compared the integration of characteristic resonance signals at 2.15 ppm 
(corresponding to [64H]) ppm from the dendrimer and resonance signals of the -N=CH- 
protons at 8.45 ppm. In the Fig. 2.25 the 
1
H NMR spectra of obtained products are compared. 
 
 
Scheme 2.9 Scheme of reaction between G3-PAMAM(-NH2)32 and salicylic aldehyde. 
 
Fig. 2.25 The 
1
H NMR spectra of a) G3-PAMAM(-NH2)32 in CD3OD, b) G3-PAMAM(-NH2)32
50Sal
  
in DMSO-d6, c) and G3-PAMAM(-NH2)32
100Sal
 in DMSO-d6. 
 
a 
b 
c 
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2.4.2 Immobilization of Ru-complexes 
 
Schiff base ruthenium complexes and their applications in catalytic processes were 
described by Verpoort group. This group of complexes were tested towards ring closing 
metathesis reaction or for the COD polymerization.
174
  
We use prepared G3-PAMAM
50Sal
 as a polymer support for Ru-complex 15. 
After reaction of G3-PAMAM
50Sal
 with Ru-complex 15 were separated as heterogeneous 
catalyst in form of a violet powder. 
 
Scheme 2.10 Immobilization reaction of Ru-complex 15 on G3-PAMAM
50Sal
. 
 
Catalytic activity of this compound was checked towards ring closing metathesis reaction  
of diethyl diallyl malonate (Scheme 2.11) using standard 
1
H NMR procedure.
175
 
 
Scheme 2.11 Standard example of RCM of diethyl diallyl malonate. 
 
I observed only maximum 65% conversion. 
Since the color of obtained violet product quickly convert into green that was completely 
inactive in test reaction as well as because of low conversion we have concluded that obtained 
heterogeneous catalyst was not promising. 
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2.5 Conclusions 
 
Synthesis of imidazolinium salts bearing ring-centered chirality was performed 
starting from N-Boc derivatives of L-alanine and L-phenylalanine as examples of amino acid 
pool representatives. The following steps of synthetic route comprised: 1) conversion of 
carboxylate into N-aryl amide via DCC activation of carboxylic group, 2) removal of Boc 
group from amine group, 3) condensation of released amine group with aromatic aldehyde,  
4) total or partial (stepwise) reduction of amide carbonyl and aldimine groups, 4) closure of 
imidazolyl ring with triethylformate. The compounds were characterized by NMR and IR 
spectroscopy and MS spectrometry, as well as other appropriate methods, like polarimetry. 
The following cationic imidazolyl ligands were isolated as chloride salts: (S)-1-(2-
hydroxybenzyl)-3-mesityl-5-methyl-4,5-dihydro-1H-imidazol-3-ium chloride 8a; (S)-1-(3,5-di-
tert-butyl-2-hydroxybenzyl)-3-mesityl-5-methyl-4,5-dihydro-1H-imidazol-3-ium chloride 8b; 
(R)-1-(2-hydroxybenzyl)-3-mesityl-5-methyl-4,5-dihydro-1H-imidazol-3-ium chloride 8c; (R)-
1-(3,5-di-tert-butyl-2-hydroxybenzyl)-3-mesityl-5-methyl-4,5-dihydro-1H-imidazol-3-ium 
chloride 8d; (S)-4-benzyl-3-(2-hydroxybenzyl)-1-mesityl-4,5-dihydro-1H-imidazol-3-ium 
chloride 13. 
Cationic imidazolylidene ligand 8a was used further to obtain the transition metal 
complexes with ruthenium(II), rhodium(I) and palladium(II) ions. When Cl2(PCy3)2Ru-
(indenylidene) starting ruthenium(II) complex, (16), was reacted with ligand 8a in toluene and 
KHMDS, the isolated product had the formula [(8a-H)2Ru(indylidene)]n (n = 1 or 2), 
identified by mass and NMR spectra. The anionic ligand 8a was coordinated via phenolic 
oxygen and imidazolylidene carbon. The pentacoordinate complex was in equilibrium 
between monomeric species (n = 1) and dimer (n  = 2), in which the 8a was a bridging ligand. 
In case of rhodium(I) and palladium(II) all attempts to obtain complexes with O,C-chelated 
imidazolylidene anion failed; instead the neutral ligand was very likely coordinated via 
phenolic oxygen, although clearly involving the phenolate oxygen but not HNC or even 
aminidinium species could not be established despite many attempts. 
The attempts to immobilize ruthenium(II) catalyst for ring closing metathesis led to 
heterogeneous catalytic material of moderate activity. The PAMAM-immobilized 
ruthenium(II) compound was unstable in catalytic reaction conditions and bleached after one 
catalytic cycle. 
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Part 3 
 
3. Experimental 
 
3.1  Materials 
 
Starting reagents amino acids with the amino group protected by t-butoxycarbonyl (boc) were 
purchased from Sigma-Aldrich and were used as received. Bis(tricyclohexylphosphine)-3-
phenyl-1H-inden-1-ylideneruthenium(II) dichloride, 16 was purchased from Strem 
Chemicals, Inc. and used as received. All other chemical compounds were purchased from 
Sigma-Aldrich and used without further purification. All solvents were dried with appropriate 
drying agents and distilled prior to use.  
All reactions and manipulations involving organometallic compounds were conducted  
in oven-dried glassware under argon atmosphere unless otherwise noted. Flash 
chromatography was performed using silica gel 60. Reactions progress was monitored  
by TLC chromatography using TLC silica gel 60 F254 plates. 
 
3.2  Measurements and equipment 
 
1
H, 
13
C and 
31
P NMR measurements were performed with a Bruker Avance II 500 
spectrometer and are reported in parts per million (ppm) with TMS as reference or using  
the residual solvent peak. Coupling constant J is given in Hz. 
Infra-red (IR) spectra were obtained using NICOLET 8700 FT-IR, Thermo SCIENTIFIC 
spectrometer with the % transmittance values reported in cm
-1
. Melting points were measured 
using MEL-TEMP® Electrothermal apparatus. Optical rotations [𝛼]𝐷
20 were performed  
on a Jasco P-1020 polarimeter apparatus operating at 20 ºC. Elemental analysis was carried 
out on AE 1108 Carlo Erba analyzer. Mass spectra were recorded on Bruker AuflexSpeed 
spectrometer. 
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3.3  Syntheses 
3.3.1 Synthesis of imidazolylidene ligands 
 
(S)-tert-butyl 1-(mesitylamino)-1-oxopropan-2-ylcarbamate, 1 
2,4,6-Trimethylaniline (2.1 mL, 15 mmol) was added  
to a solution of Boc-L-alanine (2.8 g, 15 mmol) in dry THF  
(50 mL) followed by addition of DCC (3.1 g, 15 mmol) solution in dry THF (30 mL).  
The mixture was stirred at room temperature for 18 h. Subsequently white precipitate was 
filtered off and filtrate was concentrated by rotary evaporator. The oily filtrate residue was 
purified by silica gel chromatography (DCM/MeOH) to give compound 1 (4.3 g, 93%)  
as colorless solid. M. p.: 118-120 ºC. 
1
H-NMR (CDCl3): δ 7.55 (bs, 1H, NH), 6.85 (s, 2H, ArH), 5.14 (bs, 1H, NH), 4.33 (m, 1H), 
2.24 (s, 3H, ArCH3), 2.13 (s, 6H, ArCH3) 1.46 (d, J=9.8, 3H), 1.44 (s, 9H). 
13
C-NMR (CDCl3): δ 171.5 (CO), 156.0 (CONH), 137.1, 135.3 (2xC), 130.9, 129.1 (2xCArH), 
80.4, 50.5, 28.5, 21.1, 18.4 (3xC). 
IR (KBr): 3303.9, 2979.9, 2930.8, 2853.1, 1712.9, 1683.5, 1658.9, 1529.7, 1459.3, 1402.0, 
1367.3, 1319.8, 1295.5, 1270.4, 1253.5, 1225.1, 1161.4, 1067.9, 1005.7. 
 
(S)-2-amino-N-mesitylpropanamide hydrochloride, 2 
A compound 1 (2.3 g, 7.5 mmol) and HCl solution in diethyl ether 
(2M, 25 mL) were stirred at room temperature for 5 h. Afterwards 
white precipitate was filtered off and washed with diethyl ether  
to give compound 2 (1.5 g, 82%) as colorless solid. M. p.: 257-259 ºC. 
1
H-NMR (DMSO-d6): δ 9.88 (s, 1H, NH), 8.32 (bs, 3H, NH2), 6.89 (s, 2H, ArH), 4.10  
(q, J=6.9, 1H), 2.22 (s, 3H), 2.11 (s, 6H), 1.52 (d, J=6.9, 3H). 
13
C-NMR (DMSO-d6): δ 168.1 (CO), 135.8, 134.8, 131.3, 128.3 (2xCArH), 48.3 (CHCO), 
20.5, 17.9 (2xC), 17.5. 
IR (KBr): 3274.1, 2916.8, 2857.5, 2664.2, 2588.5, 2456.4, 1671.5, 1611.2, 1587.1, 1540.8, 
1469.0, 1391.9, 1377.4, 1245.3, 1199.5, 1126.7, 1100.2, 997.5, 977.8, 957.0, 845.6. 
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(S)-2-(2-hydroxybenzylideneamino)-N-mesitylpropan-
amide, 3a  
MeONa was added to a solution of 2 (1.5 g, 6.2 mmol)  
in MeOH (35 mL) until reaction mixture gained neutral pH. 
Afterwards salicylaldehyde (0.65 mL, 6.2 mmol) was added and resulting mixture was stirred 
at room temperature for 16 h. A yellow solid was filtered off and washed with water and 
hexane to give compound 3a (1.6 g, 83%). M.p.: 166-167 ºC. [𝛼]𝐷
20= +171 (c 1, CHCl3). 
1
H-NMR (CDCl3): δ 12.45 (s, 1H, OH), 8.50 (s, 1H, CH=N), 7.38 (t, J=7.4, 1H), 7.36-7.33 
(m, 2H), 7.31 (bs, 1H), 7.00 (d, J=8.3, 1H), 6.95 (t, J=7.4, 1H), 6.87 (s, 2H, ArH), 4.20  
(q, J=6.9, 1H), 2.25 (s, 3H), 2.15 (s, 6H), 1.68 (d, J=6.9, 3H). 
13
C-NMR (CDCl3): δ 170.6 (CO), 166.9 (C=N), 160.6, 137.2, 134.9, 133.3, 132.2, 130.5, 
129.0 (2xCArHMes), 119.4, 118.5, 117.1, 69.2, 21.3, 20.9, 18.2 (2xC). 
IR (KBr): 3254.3, 2915.8, 1659.9, 1635.3, 1525.4, 1462.3, 1387.1, 1296.4, 1278.6, 1232.8, 
1224.6, 1101.6, 1048.6, 987.4, 903.0, 851.4, 750.7, 716.4, 460.4. 
 
(S)-2-(3,5-di-tert-butyl-2-hydroxybenzylideneamino)-N-
mesitylpropanamide, 3b 
MeONa was added to a solution of compound 2 (1.3 g, 
5.4 mmol) in MeOH (30 mL) untill reaction mixture 
gained neutral pH. Afterwards, 3,5-di-tert-butyl-2-
hydroxybenzaldehyde (1.2 g, 5.1 mmol) was added and resulting mixture was stirred at room 
temperature for 16 h. A yellow solid was filtered off and washed with water and hexane  
to give compound 3b (1.8 g, 83%). M. p.: 234-236 ºC. 
1
H-NMR (CDCl3): δ 12.88 (s, 1H, OH), 8.51 (s, 1H, CH=N), 7.46 (d, J=2.4, 1H), 7.41  
(bs, 1H, NHCO), 7.17 (d, J=2.4, 1H), 6.89 (s, 2H, ArH), 4.18 (q, J=6.9, 1H), 2.26 (s, 3H), 
2.18 (s, 6H), 1.69 (d, J=6.9, 3H), 1.44 (s, 9H), 1.32 (s, 9H). 
13
C-NMR (CDCl3): δ 170.8 (CO), 168.0 (C=N), 157.7 (CArOH), 141.0, 137,1, 137.0, 135.0 
(2xC), 130.6, 129.0 (2xCArHMes), 128.2, 126.7, 117.6, 69.4, 35.1, 34.2, 31,5, 29.4, 21.5, 20.9, 
18.3 (2xC). 
IR (KBr): 3219.1, 3052.3, 2953.9, 2915.8, 2869.1, 1655.6, 1608.8, 1545.2, 1466.1, 1440.6, 
1361.0, 1276.2, 1248.2, 121.5, 1136.8, 1057.8, 882.3, 850.9, 774.3, 695.2. 
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(S)-2-(2-hydroxybenzylamino)-N-mesitylpropanamide 
hydrochloride, 4a 
NaBH4 (0.16 g, 4.2 mmol) was added to a solution  
of compound 3a (0.50 g 1.6 mmol) in dry THF (30 mL). 
The mixture was stirred at room temperature for 16 h and then at reflux temperature for 2 h. 
Thereafter, the reaction mixture was cooled down and distilled water was added. After ca 4 h 
white precipitate was filtered off and dried to give (S)-2-(2-hydroxybenzylamino)-N-mesityl-
propanamide (0.37 g, 74%) as colorless solid.  
1
H-NMR (CDCl3): δ 7.28 (bs, 1H, OH), 7.20 (t, J=7.7, 1H, ArH), 7.03 (d, J=7.7, 1H, ArH), 
6.92 (s, 2H, ArH), 6.88-6.79 (m, 2H, ArH), 4.20 (d, J=13.6, 1H), 3.83 (d, J=13.4, 1H), 3.41  
(q, J=7.5, 1H), 2.28 (s, 3H), 2.18 (s, 6H), 1.55 (d, J=7.3, 3H). 
13
C-NMR (CDCl3): δ 172.5 (CO), 157.9 (CArOH), 137.4, 134.9, 130.5, 129.1, 128.8, 122.0, 
119.4, 116.5, 55.9, 50.6, 20.9, 20.0, 18.4. 
A solution of HCl in diethyl ether (1M, 0.5 mL) was added to a solution of (S)-2-(2-
hydroxybenzylamino)-N-mesitylpropanamide (0.33 g, 1.1 mmol) in chloroform (9 mL).  
The mixture was stirred at room temperature for 3 h. Afterwards, a white precipitate was 
filtered off and washed with diethyl ether to give compound 4a (0.33 g, 90%) as a colorless 
solid. 
1
H-NMR (DMSO-d6): δ 10.27 (bs, 1H), 10.14 (s, 1H), 9.46 (bs, 1H), 9.15 (bs, 1H), 7.44  
(d, J=6.3, 1H), 7.23 (t, J=6.6, 1H), 7.00 (d, J=7.8, 1H), 6.90 (s, 2H), 6.84 (t, J=7.4, 1H), 4.18 
(bs, 1H), 4.10 (bs, 2H), 2.23 (s, 3H), 2.13 (s, 3H), 1.62 (d, J=6.9, 3H).  
13
C-NMR (DMSO-d6): δ 167.2 (CO), 156.0 (CArOH), 135.9, 134.7, 131.5, 131.2 (2xC), 130.3, 
128.4 (2xC), 118.9, 117.9, 115.5, 55.1, 43.7, 20.5, 18.0 (2xC), 16.5. 
IR (KBr): 3042.3, 1660.0, 1608.3, 1525.8, 1505.6, 1486.0, 1462.3, 1378.7, 1354.1, 1317.7, 
1270.0, 855.7, 759.3. 
MS(ESI): m/z calculated for C19H25N2O2 [M+H]
+
 313.1838, observed 313.1802. 
 
(S)-2-(3,5-di-tert-butyl-2-hydroxybenzylamino)-N-
mesitylpropanamide hydrochloride, 4b 
NaBH4 (0.15 g, 4.0 mmol) was added to a solution  
of compound 3b (0.50 g 1.2 mmol) in dry THF (30 mL). 
The mixture was stirred at room temperature for 16 h and 
then at reflux temperature for 2 h. Thereafter, the 
reaction mixture was cooled down and distilled water was added. After ca 4 hours a white 
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precipitate was filtered off and dried to give (S)-2-(3,5-di-tert-butyl-2-hydroxybenzylamino)-N-
mesitylpropanamide as colorless solid. 
Conc. HClaq (0.2 mL) was added to a solution of (S)-2-(3,5-di-tert-butyl-2-hydroxy- 
benzylamino)-N-mesitylpropanamide in chloroform (9 mL). The mixture was stirred at room 
temperature for 3 h. Afterwards, a white precipitate was filtered off and washed with diethyl 
ether to give compound 4b (0.35 g, 65%) as a colorless solid.  
1
H-NMR (CD3OD): δ 7.40 (d, J=2.4, 1H), 7.27 (d, J=2.4, 1H), 6.92 (s, 2H), 4.31-4.21  
(m, 3H), 2.25 (s, 3H), 2.18 (s, 6H), 1.73 (d, J=7.4, 3H), 1.40 (s, 9H), 1.29 (s, 9H).  
13
C-NMR (CD3OD): δ 168.0, 151.7 (CArOH), 143.8, 139.4, 137.4, 134.9 (2xC), 130.2, 128.5 
(2xC), 125.7, 125.5, 120.4, 55.7, 46.5, 34.6, 33.9, 30.5, 29.1, 19.6, 17.1 (2xC), 15.9. 
 
(S,E)-2-(N-(2-hydroxybenzyl)-N’-mesitylformamimidamido) 
propanoic acid, 6 
A compound 4a
.
(0.30 g, 1.4 mmol) was suspended in dry 
toluene (15 mL). Afterwards (EtO)3CH (2.5 mL) was added. 
The reaction mixture was stirred at reflux temperature for 6 
hours. Afterwards the mixture was cooled down and stirred at 
room temperature for 12 h. Then solvent was removed in vacuo. A dry residue was purified 
by silica gel chromatography (DCM/iPrOH). The mixture of products 6 and 6’, in 1.0:0.8 
molar ratio were isolated (~35%). 
1
H NMR (DMSO-d6): two set of resonances of relative intensity 1:0.7: 
δ 9.57 (s, 1H), 9.37 (s, 1H), 8.46 (s, 1H), 7.09-7.03 (m, 2H), 6.87 (s, 2H), 6.83-6.78 (m, 1H), 6.75  
(t, J=7.5, 1H), 4.62-4.49 (m, 1H), 4.37 (q, J=7.5, 1H), 4.29 (d, J=16.0, 1H), 2.21 (s, 3H), 2.05 (s, 6H), 
1.49 (d, J=7.5, 3H).  
δ 9.78 (s, 1H), 8.93 (s, 1H), 8.28 (s, 1H), 7.20 (d, J=7.5, 1H), 7.12 (td, J=7.5, 1.5, 1H), 6.85 (s, 2H), 
6.83-6.78 (m, 2H), 4.62-4.49 (m, 3H), 2.21 (s, 3H), 2.03 (s, 6H), 1.25 (d, J=7.5, 3H). 
13
C NMR (DMSO-d6): δ 169.6, 169.2, 164.1, 163.3, 155.1, 154.7, 135.5, 135.3, 135.0, 134.7 (2C), 
132.0, 131.77, 129.3, 128.6, 128.2 (2C), 128.1 (3C), 127.9, 127.8, 124.0, 123.2, 119.0, 118.8, 115.1, 
114.9, 56.0, 52.0, 45.3, 41.2, 20.4 (2C), 17.8 (2C), 17.7 (2C), 17,4, 14.7. 
IR (KBr) : 3250.2, 2920.3, 1655.3, 1608.2, 1510.0, 1487.6, 1458.0, 1398.2, 1375.3, 1352.6, 1295.4, 
1240.7, 1105.4, 850.8, 755.6, 730.8. 
MS(ESI): m/z calculated for C20H24N2O3 [M+Na]
+
 363.1685, observed 363.1625. 
 
 
77 
Reaction of (S)-2-(3,5-di-tert-butyl-2-hydroxybenzylamino)-N-mesitylpropanamide hydro- 
chloride, 4b, with triethyl orthoformate. 
A compound 4b (0.30 g, 1.1 mmol) was suspended in dry toluene (15 mL). Afterwards 
(EtO)3CH (2.0 mL) was added. The reaction mixture was stirred at reflux temperature  
for 16 h. Afterwards, the mixture was cooled down and solvent was removed in vacuo. A dry 
residue was purified by silica gel chromatography (DCM/MeOH). 
Two products 5b and 5b’ were isolated and characterized by NMR spectroscopy: 
Product 5b 
1
H-NMR (CDCl3): δ 7.12 (d, J=2.0, 1H), 6.96 (bs, 1H), 6.95 (d, J=2.0, 1H), 6.87 (bs, 1H), 
5.80 (s, 1H), 4.61 (s, 1H), 4.47 (d, J=17.0, 1H), 4.31 (d, J=17.0, 1H), 3.99-3.92 (m, 1H), 
3.89-3.82 (m, 1H), 3.75-3.69 (m, 1H), 3.59-3.52 (m, 1H), 2.39 (s, 3H), 2.29 (s, 3H), 2.23  
(s, 3H), 1.56 (s, 3H), 1.32 (t, J=7.0, 3H), 1.28 (s, 9H), 1.19 (t, J=7.0, 3H), 1.11 (s, 9H). 
13
C-NMR (CDCl3): δ 173.4 (CO), 149.6, 144.1, 138.5, 138.2, 137.8, 135.3, 129.2, 129.1, 
123.4, 121.7, 121.4, 107.1, 96.7, 67.6, 67.2, 65.8, 44.7, 34.4 (2xC), 31.6, 29.7, 29.5, 21.1, 
18.8, 18.4, 17.8, 15.6, 15.4. 
Product 5b’ 
1
H-NMR (CDCl3): δ 8.37 (bs, 1H), 8.17 (bs, 1H), 7.29 (bs, 1H), 6.89 (s, 2H), 5.49 (s, 1H), 
4.00-3.92 (m, 1H), 3.86-3.73 (m, 2H), 3.67-3.60 (m, 1H), 2.26 (s. 3H), 2.10 (s, 6H), 1.83 (s, 
3H), 1.29 (t, J=7.0, 3H), 1.17 (t, J=7.0, 3H).  
13
C-NMR (CDCl3): δ 170.1 (CO), 160.5, 136.8, 135.1 (2xC), 131.0, 128.8 (2xC), 103.2, 66.9, 
66.6, 63.5, 21.2, 20.9, 18.2 (2xC), 15.5, 15.4. 
 
(S)-2-{[1-(mesitylamino)propan-2-ylamino]methyl}phenol 
dihydrochloride, 7a 
The mixture of compound 3a (2.0 g, 6.6 mmol) and  
a solution of BH3
.
THF complex (1M, 40 mL) was stirred  
at reflux temperature for 24 h. Then the mixture was cooled down to room temperature and 
MeOH was added drop-wise till all bubbling ceased. Conc. HClaq (12M, 1mL) was added 
and the solvent was removed by evaporation. The resulting solid was redissolved in MeOH 
and the solvent was again evaporated to remove the boron as B(OMe)3. MeOH was added and 
removed in this way twice more. To a dry residue chloroform was added and product was left 
to precipitate. A desired product was filtered off and dried to give compound 7a (1.6 g, 65%) 
as a colorless solid. 
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1
H-NMR (DMSO-d6): δ 10.37 (bs, 1H), 9.54 (bs, 2H), 8.35 (s, 1H), 7.49 (d, J=6.6, 1H), 7.23 
(t, J=7.3, 1H), 6.99 (d, J=8.0, 1H), 6.93 (s, 2H), 6.84 (t, J=7.4, 1H), 4.20 (d, J=13.1, 1H), 
4.12 (d, J=13.1, 1H), 3.79 (bs, 1H), 3.58 (bm, 1H), 3.33 (bs, 1H), 2.40 (s, 6H), 2.21 (s, 3H), 
1.55 (d, J=6.45, 3H). 
13
C-NMR (DMSO-d6): δ 156.0 (CArOH), 131.7, 131.5, 130.4, 130.1 (2xC), 119.0, 118.0, 
115.4, 79.2, 51.5, 51.1, 42.6, 20.3, 18.0 (2xC), 14.3.  
IR (KBr): 3154.0, 2957.3, 2725.9, 2406.7, 1598.7, 1575.1, 1459.4, 1393.8, 1270.4, 1245.3, 
1185.0, 1131.5, 1105.9, 854.8, 757.4, 579.0, 497.5, 474.4. 
MS(ESI): m/z calculated for C19H26N2O [M+H]
+
 299.2045, observed 299.2003. 
 
(S)-1-(2-hydroxybenzyl)-3-mesityl-5-methyl-4,5-dihydro-
1H-imidazol-3-ium chloride, 8a 
A compound 7a (1.0 g, 2.7 mmol) was suspended in dry 
toluene (30 mL), followed by addition of (EtO)3CH (5.5 mL). 
The reaction mixture was stirred at reflux temperature  
for 24 h. Afterwards the mixture was cooled down and solvent was removed by vacuum.  
To a dry residue chloroform (10 mL) was added and a white precipitate was filtered off and 
dried in vacuum to give compound 8a (0.82g, 88%) as a colorless solid. M. p.: 268-269 ºC.  
1
H-NMR (DMSO-d6,): δ 10.25 (s, 1H), 8.90 (s, 1H), 7.36 (d, J=7.5, 1H), 7.23 (t, J=7.5, 1H), 
7.04 (s, 2H), 6.99 (d, J=8.0, 1H), 6.85 (t, J=7.4, 1H), 4.85 (d, J=14.6, 1H), 4.58 (d, J=14.6, 
1H), 4.27-4.21 (m, 2H), 3.79-3.74 (m, 1H), 2.27 (s, 3H), 2.24 (bs, 6H), 1.44 (d, J=6.0, 3H).  
13
C-NMR (DMSO-d6,): δ 159.0 (CArOH), 156,4, 139.3, 135.5 (2xC), 131.0, 130.8, 129.3 
(2xC), 119.2, 119.1, 115.6, 56.9, 55.7, 45.2, 20.5, 17.9, 17.1 (2xC). 
1
H-NMR (CDCl3): δ 8.98 (s, 1H), 7.41 (d, J=8.0, 1H), 7.15 (t, J=8.0, 1H), 7.05 (d, J=7.5, 
1H), 8.86-6.76 (bs, 2H), 6.74 (t, J=7.5, 1H), 5.31 (d, J=14.0, 1H), 4.41 (d, J=14,0 1H), 4.32-
4.23 (m, 1H), 4.14 (t, J=10.0, 1H), 3.60-3.53 (m, 1H), 2.27 (s, 6H), 2.23 (s, 1H), 1.48 (d, 
J=7.0, 3H). 
IR (KBr): 3022.9, 2999.7, 2948.1, 2875.8, 2723.9, 2613.6, 1644.0, 1597.3, 1512.9, 1481.1, 
1457.4, 1376.4, 1335.9, 1269.4, 1215.9, 1173.9, 1141.2, 1110.8, 1043.3, 994.1, 853.8, 756.4, 
659.1, 577.6, 527.9. 
MS (ESI): m/z calculated for C20H24N2O [M-Cl]
+
 309.1967, found 309.1977;  
Anal. calcd: C 69.65, H 7.31, N 8.12, found: C 69.50, H 8.49, N 8.12.  
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The compound 7b (S)-2,4-di-tert-butyl-6-{[1-(mesitylamino)propan-2-ylamino]methyl}- 
phenol dihydrochloride was obtained by the same procedure as 7a. and used further (see 
synthesis of 8b). The compounds 7c and 7d were obtained by the same procedure as 7a, and 
their analytical data confirmed the identity and purity. 
7c: MS(ESI): m/z calculated for C19H26N2O [M+H]
+
 299.2045, observed 299.2010. 
7d: MS(ESI): m/z calculated for C27H42N2O [M+H]
+
 411.3297, observed 411.3307. 
IR (KBr): 3184.8, 2960.7, 2741.2, 2391.7, 1701.7, 1584.1, 1554.6, 1518.8, 1482.1, 1440.1, 
1393.9, 1362.2, 1282.1, 1224.2, 1202.7, 1169.9, 1125.9, 879.4, 853.4, 758.2.  
 
(S)-1-(3,5-di-tert-butyl-2-hydroxybenzyl)-3-mesityl-5-
methyl-4,5-dihydro-1H-imidazol-3-ium chloride, 8b 
The mixture of a compound 3b (1.5 g, 3.5 mmol) and  
a solution of BH3
.
THF complex (1M, 20 mL) was stirred  
at reflux temperature for 24 h. Then the mixture was 
cooled down to room temperature and MeOH was added 
drop-wise till all bubbling ceased. Conc. HClaq (12M, 1ml) was added and the solvent was 
removed by evaporation. The resulting solid was redissolved in MeOH and the solvent was 
again evaporated to remove the boron as B(OMe)3. MeOH was added and removed and 
repeated twice. Dry residue was suspended in toluene (15 mL) and (EtO)3CH (6,5 mL) was 
added. The reaction mixture was stirred at reflux temperature for 14 hours. Afterwards  
the mixture was cooled down. A white precipitate was filtered off and washed with pentane  
to give compound 8b (0.68 g, 42%) as a colorless solid. M. p.: 270-271 ºC. [𝛼]𝐷
20= -1.1  
(2, MeOH). 
1
H-NMR (DMSO-d6): δ 8.95 (s, 1H, NCHN), 8.85 (s, 1H, OH), 7.25 (s, 1H, ArH), 7.21  
(s, 1H, ArH), 7.04 (s, 2H, ArH), 5.20 (d, J=15.0, 2H), 4.87 (d, J=15.0, 2H), 4.28-4.17  
(m, 2H), 3,80-3.74 (m, 1H), 2.26 (bs, 9H), 1.41 (d, J=5.8, 3H), 1.38 (s, 9H), 1.27 (s, 9H).  
13
C-NMR (DMSO-d6): δ 158.2, 151.7 (CArOH), 142.1, 139.2, 138.5, 135.5, 131.0, 129.3, 
124.9, 123.4, 122.2, 56.8, 56.1, 45.9, 34.7, 33.9, 31.3, 29.7, 20.5, 17.9, 17.0. 
IR (KBr): 3004.6, 2949.6, 1636.3, 1481.1, 1444.9, 1361.0, 1291.6, 1251.6, 1223.1, 1133.9, 
991.7, 850.5, 693.3, 573.2. 
MS(ESI): m/z calculated for C28H41N2O [M]
+
 421.3219, observed 421.3258. 
Anal. calcd: C 73.57, H 9.04, N 6.13, found: C 73.81, H 9.13, N 6.06. 
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Compounds 8c and 8d, which are the enantiomers of 8a and 8b, respectively, were obtained 
from Boc-D-alanine by the same procedures as their S analogues. The small chemical shift 
differences in the 
1
H NMR spectra within pairs of enantiomers were observed and discussed  
in results and discussion section. 
 
(R)-1-(2-hydroxybenzyl)-3-mesityl-5-methyl-4,5-dihydro-
1H-imidazol-3-ium chloride, 8c 
1
H-NMR (DMSO-d6,): δ 10.40 (s, 1H), 8.99 (s, 1H), 7.36 
(d, J=6.1, 1H), 7.22 (t, J=8.0, 1H), 7.06 (d, J=8.0, 1H), 7.03 
(s, 2H), 6.84 (t, J=6.6, 1H), 4.89 (d, J=14.6, 1H), 4.58  
(d, J=14.6, 1H), 4.30-4.17 (m, 2H), 3.79-3.74 (m, 1H), 2.27, 2.24 (s, 9H), 1.44 (d, J=6.1, 3H). 
13
C-NMR (DMSO-d6,): δ 159.0 (CArOH), 156.5, 139.2, 135.5 (2xC), 131.0, 130.71, 130.1, 
129.3 (2xC), 119.1, 115.7, 56.9, 55.7, 45.1, 20.5, 17.9, 17.1 (2xC). 
Anal. calcd: C 69.65, H 7.31, N 8.12, found: C 68.94, H 7.11, N 8.11. 
 
(R)-1-(3,5-di-tert-butyl-2-hydroxybenzyl)-3-mesityl-5-
methyl-4,5-dihydro-1H-imidazol-3-ium chloride, 8d 
1
H-NMR (DMSO-d6): δ 9.00 (s, 1H), 8.93 (s, 1H), 7.23 
(d, J=2.4, 1H), 7.21 (d, J=2.5, 1H), 7.03 (s, 2H), 5.23  
(d, J=14.9, 1H), 4.82 (d, J=14.9, 1H), 4.26-4.17  
(m, 2H), 3.78-3.74 (m, 1H), 2.26 (s, 9H), 1.41 (d, J=6.0, 
3H), 1.37 (s, 9H), 1.27 (s, 9H).  
13
C-NMR (DMSO-d6,): δ 158.1 (CArOH), 151.8, 141.9, 139.2, 138.5, 135.5 (2xC), 130.9, 
129.3 (2xC), 124.9, 123.4, 122.2, 56.7, 55.9, 45.9, 34.7, 33.9, 31.3, 29.7, 20.4, 17.9, 17.1 
(2xC). 
MS(ESI): m/z calculated for C28H41N2O[M]
+
 421.3219, observed 421.3074. 
 
(S)-N-(1-(mesitylamino)-1-oxo-3-phenylpropan-2-yl)-3,3-
dimethylbutanamide, 9 
2,4,6-Trimethylaniline (2.7 mL, 20 mmol) was added to  
a solution of Boc-L-alanine (5.3 g, 20 mmol) in dry THF 
(100 mL), followed by addition of DCC (4.1 g, 20 mmol) 
solution in dry THF (20 mL). The mixture was stirred at room temperature for 18 h. 
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Subsequently white precipitate was filtered off and filtrate was concentrated by using a rotary 
evaporator. The oily filtrate residue was purified by crystallization in ethyl acetate to give 
compound 9 (5.6 g, 74%, 2 steps) as a colorless solid.  
1
H-NMR (CDCl3): δ 7.45 (s, 1H, NH), 7.31-7.21 (m, 5H), 6.79 (s, 2H), 5.25 (d, J=7.6, 1H), 
4.57 (q, J=7.40 1H), 3.22-3.08 (m, 2H), 2.22 (s, 3H), 1.96 (s, 6H), 1.42 (s, 9H). 
13
C-NMR (CDCl3): δ 170 (CO), 136.9, 136.8, 135.1 (2xC), 130.7, 129.5 (2xC) 128.8, 128.7, 
126.9, 80.4, 56.1, 37.8, 28.3 (3xC), 20.9, 18.1 (2xC). 
 
(S)-2-amino-N-mesityl-3-phenylpropanamide hydrochloride, 10 
A solution of a compound 9 (4.0 g, 10.0 mmol) and a solution 
of HCl in diethyl ether (1M, 65 mL) was stirred for 15 h. 
Afterwards a white precipitate was filtered off and washed 
with diethyl ether to give compound 10 (2.8 g, 84%) as a colorless solid.  
1
H-NMR (DMSO-d6): δ 10.19 (s, 1H), 8.56 (bs, 3H), 7.41 (d, J=7.2, 2H), 7.34 (t, J=7.2, 2H), 
7.29-7.26 (m, 1H), 6.82 (s, 2H), 4.42 (t, J=7.4, 1H), 3.27-3.23 (m, 1H), 3.18-3.14 (m, 1H), 
2.20 (s, 3H), 2.00 (bs, 6H). 
13
C-NMR (DMSO-d6): δ 166.5, 135.7, 135.2 (2xC), 134.7, 131.3, 129.6 (3xC), 128.5 (2xC), 
128.3 (2xC), 127.1, 53.5, 37.2, 20.4, 18.0 (2xC). 
 
(S)-2-(2-hydroxybenzylideneamino)-N-mesityl-3-
phenylpropanamide, 11 
MeONa was added to a solution of compound 10 (2.8 g,  
8.8 mmol) in MeOH (35 mL) until reaction mixture gained 
neutral pH. Afterwards salicylaldehyde (0.95 mL, 8.8 mmol) 
was added and the resulting mixture was stirred at room temperature for 20 h. A yellow 
precipitate was filtered off and washed with water (100 mL) and hexane (40 ml), followed by 
crystallization in ethyl acetate to give compound 11 (2.4 g, 70%) as a yellow solid. 
1
H-NMR (CDCl3): δ 12.42 (s, 1H, OH), 7.99 (s, 1H, CH=N), 7.40 (bs, 1H, NH), 7.36-7.31 
(m, 1H), 7.26-7.20 (m. 2H), 7.18 (m, 3H), 7.12 (dd, J=7.5, 1.6, 1H), 6.97 (d, J=8.2, 1H), 6.87 
(td, J=8.3, 7.6, 1H), 6.85 (s, 2H, ArHMes), 4.24-4.20 (m, 1H), 3.52-3.48 (m, 1H), 3.25-3.20  
(m, 1H), 2.24 (s, 3H), 2.07 (s, 6H). 
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13
C-NMR (CDCl3): δ 169.1 (CO), 167.8 (CH=N), 160.5, 137.0, 136.8, 134.8 (2xC), 133.3, 
132.2, 130.5 (3xC), 129.9 (2xC), 128.9 (2xC), 128.5, 126.9, 119.3, 118.3, 117.0, 75.6, 41.0, 
20.9, 18.2 (2xC). 
IR (KBr): 2921.3, 2858.2, 1671.7, 1632.9, 1524.4, 1482.8, 1360.2, 1280.4, 1247.5, 1194.8, 
1151.5, 1032.0, 922.5, 857.0, 762.3, 737.4, 697.1, 437.5. 
Anal. calcd: C 77.69, H 6.78, N 7.25, found: C 77.71, H 6.98, N 7.25. 
 
(S)-4-benzyl-3-(2-hydroxybenzyl)-1-mesityl-4,5-dihydro-
1H-imidazol-3-ium chloride, 13 
The mixture of a compound 11 (2.3 g, 6.0 mmol) and  
a solution of BH3
.
THF complex (1M, 35 mL) was stirred 
at reflux temperature for 14 h. Then the mixture was 
cooled down to room temperature and MeOH was added 
drop-wise till all bubbling ceased. Conc. HClaq (12M, 1mL) was added and the solvent was 
removed by evaporation. The resulting solid was redissolved in MeOH and the solvent was 
again evaporated to remove the boron side product B(OMe)3. MeOH was added and removed 
in this way twice more. A dry residue (containing not isolated compound 12) was suspended 
in toluene (40 mL) and then (EtO)3CH (6.5 mL) was added. The reaction mixture was stirred 
at reflux temperature for 14 h. Afterwards the mixture was cooled down. A white precipitate 
was filtered off, washed with diethyl ether and dried in vacuum. Then a white solid was 
crystallized from DCM/pentane to give compound 13 (0.90 g, 38%) as a colorless solid.  
[𝛼]𝐷
20 = + 44.7. (1, MeOH).  
1
H-NMR (DMSO-d6): δ 10.44 (s, 1H, OH), 8.97 (s, 1H, NCHN), 7.38-7.34 (m, 3H), 7.33-
7.28 (m, 3H), 7.26 (td, J=7.8, 1.6, 1H), 7.05 (d, J=7.7, 1H), 6.97 (bs, 2H, ArHMes), 6.86  
(t, J=7.4, 1H), 5.00 (d, J=14.5, 1H), 4.72 (d, J=14.5, 1H), 4.46-4.38 (m, 1H), 4.19  
(t, J=11.8, 1H), 3.78 (dd, J=8.10, 11.80, 1H), 3.27-3.16 (m, 2H), 2.23 (s, 3H), 2.16 (bs, 3H), 
1.82 (bs, 3H). 
13
C-NMR (DMSO-d6): δ 159.6 (NCHN), 156.6 (COH), 139.3, 135.4, 135.0 (2xC), 131.1, 
130.8, 130.3, 129.9(2xC), 129.2 (2xC), 128.8 (2xC), 127.2, 119.1, 118.9, 115.7, 59.7, 54.1, 
45.7, 35.7, 20.5, 17.2, 16.5. 
IR (KBr): 2952.2, 1644.2, 1600.8, 1497.1, 1478.9, 1458.2, 1378.1, 1285.2, 1228.2, 1213.9, 
1134.4, 760.1, 739.4, 704.5, 535.5. 
MS (ESI): m/z calculated for C26H29N2O [M-Cl]+ 385.2280, observed 385.2287. 
Anal. calcd: C 74.18, H 6.94, N 6.66, found: C 73.49, H 6.78, N 6.52. 
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Further purification of the filtrate using silica gel chromatography (DCM/MeOH) afforded the 
by-product 14. The attempts to identify it by NMR and MS did not provide conclusion on its 
structure.  
 
1
H-NMR (CDCl3): δ 8.48 (bs, 1H), 7.46 (s, 1H), 7.24-7.13 (m, 7H), 6.95 (d, J=8.0, 1H), 6.83 
(t, J=7.4, 1H), 6.76 (s, 1H), 6.71 (s, 1H), 3.38 (d, J=14.0, 1H), 3.21 (dd, J=18.2; 13.5, 2H), 
3.15 (d, J=14.0, 1H), 2.19 (s, 3H), 1.61 (s, 1H), 1.49 (s, 3H), 1.09 (s, 3H).  
13
C-NMR (CDCl3): δ 180.9, 155.9, 155.7, 139.2, 135.7, 135.6 (2xC), 134.6, 132.6, 130.7, 
129.3, 129.2, 129.1, 128.3, 127.8, 127.3, 122.3, 120.8, 118.5, 77.2, 42.4, 40.8, 20.5, 17.3, 16.7. 
1
H-NMR (DMSO-d6): δ 9.19 (s, 1H), 7.86 (s, 1H), 7.27-7.15 (m, 4H), 7.14-7.10 (m, 2H), 7.05 
(t, J=7.5, 1H), 6.81-6.77 (m, 2H), 6.75 (bs, 1H), 6.72 (t, J=7.5, 1H), 3.20 (d, J=14.0, 1H), 
3.17-3.08 (m, 3H), 2.16 (s, 3H), 1.52 (s, 3H), 1.03 (s, 3H). 
13
C-NMR (DMSO-d6):δ 180.9 (CON), 155.9, 153.9, 137.9, 135.4 (2xC), 135.2, 132.4, 130.5, 
128.7, 128.6 (2xC), 128.0, 127.9, 126.7, 121.7, 118.7, 115.6, 75.7, 41.5, 36.8, 20.4, 16.9, 
16.4. 
MS(ESI): m/z observed; 439.1944. 
Anal.; found: C 67.30, H 7.02, N 5.86. 
 
1
H and 
13
C assignments of the compounds 8a and 8b and 13 
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Table 3.1 
1
H and 
13
C assignments of the compounds 8a and 8b and 13 at 295K in DMSO-d6 
 
 
 
3.3.2 Coordination of ligand 8a to metal complexes 
 
3.3.2.1 Coordination of ligand 8a to Ru(II) complex 15 
NMR scale experiment: A 10 mL vial was charged with ligand 8a (10 mg, 0.029 mmol) and 
compound 15 (16 mg, 0.019 mmol). Afterwards dry toluene (0.8 mL) was added, followed by 
addition of a solution of KHMDS in toluene (1M, 0.12 mL, 0.060 mmol). The mixture was 
stirred for 5 minutes, thereafter 0.7 mL of this solution was transferred in a NMR tube. 
Additionally, a probe with CDCl3 was placed into the NMR tube as calibration lock. 
31
P NMR 
measurements were recorded after 0.5h, 1h, 2h, 4h, 6h, 21h.  
 
General procedure: A 15 mL vial was charged with ligand 8a (50 mg, 0.145 mmol) and 
compound 15 (79 mg, 0.096 mmol). Afterwards dry toluene (2.5 mL) was added followed by 
addition of KHMDS solution in toluene (1M, 0.58 mL, 0.290 mmol). The mixture was stirred 
under argon and after 0.5h, 1h, 2h, 4h, 6h, 21h. 0.5 mL samples were taken and dried. 
Afterwards dry samples were dissolved in CDCl3 and 
1
H and 
31
P NMR spectra were recorded. 
Atom label
1
H 
13
C 
1
H 
13
C 
1
H 
13
C 
1 2.27 20.5 2.26 17.1 or 20.5 2.23 20.5
2 - 139.3 - 139.2 - 139.3
3 7.04 129.3 7.04 129.4 6.97 129.2
4 - 135.5 - 135.5 - 135.0
5 2.24 17.1 2.26 17.1 or 20.5 1.82, 2.16 17.1, 16.5
6 - 131.0 - 131.1 - 131.1
7 3.79-3.74, 4.27-4.21 56.9 3.80-3.74, 4.28-4.17 56.8 3.80-3.75, 4.18 54.1
8 4.27-4.21 55.7 4.28-4.17 56.1 4.45-4.43 59.7
9 1.44 17.9 1.40 17.9 3.26-3.16 35.7
10 4.85, 4.58 45.2 5.20, 4.87 45.8 4.73, 5.00 45.7
11 - 119.1 - 122.2 - 119.1
12 7.36 130.8 7.21 124.9 7.40-7.34 130.8
13 6.85 119.2 - 142.1 6.85 118.9
14 - - - 33.9 - -
15 - - 1.27 31.35 - -
16 7.23 130.2 7.25 123.5 7.25 130.3
17 6.99 115.6 - 138.6 7.05 115.7
18 - - - 34.8 - -
19 - - 1.38 29.7 - -
20 - 156.4 - 151.7 - 156.6
21 8.90 159.0 8.95 158.2 8.97 159.6
22 10.25 - 8.85 - 10.44 -
23 - - - - - 135.4
24 - - - - 7.40-7.34, 7.32-7.28 129.9, 128.8, 130.8
8a 8b 13
85 
 
3.3.2.2 Coordination of ligand 8b to Ru(II) complex 15 
NMR scale experiment: A 10 mL vial was charged with ligand 8b (10 mg, 0.021 mmol) and 
compound 15 (13 mg, 0.014 mmol). Dry toluene (0.8 mL) was added, followed by addition  
of a solution of KHMDS in toluene (1M, 0.12 mL, 0.060 mmol). The mixture was stirred  
for 5 min and afterwards 0.7 mL of this solution was transferred in a NMR tube. Additionally 
a probe with CDCl3 was placed into the NMR tube as calibration lock. 
31
P NMR 
measurements were recorded after 0.5h, 1h, 2h, 4h, 6h, 21h.  
 
3.3.2.3 Coordination of ligand 8a to Ru(II) complex 19 
Variant I: A 15 mL vial was charged with ligand 8a (30 mg, 0.087 mmol), compound 19  
(83 mg, 0.087mmol) and NaH (4 mg, 0.174 mmol), followed by addition of dry THF (2 mL).  
 
Variant II: A 15 mL vial was charged with ligand 8a (0.10 g, 0.29 mmol), compound 19 
(0.28 g, 0.29 mmol), followed by addition of dry toluene (3 mL) and a solution of KHMDS in 
toluene (1M, 2.5 mL).  
 
Variant III: A 15 mL vial was charged with ligand 8a (30 mg, 0.087 mmol), compound 19  
(63 mg, 0.066 mmol) and tBuOK (15 mg, 0.132 mmol), followed by addition of dry THF (2 mL). 
 
The reaction mixtures were stirred under argon at room temperature for 24 h. Afterwards the 
mixtures were dried and flash silica gel chromatography was performed (DCM/iPrOH). 
 
3.3.2.4 Coordination of ligand 8a to Ru(II) complex 16 
Variant I: A 50 mL flask was charged with ligand 8a (0.10 g, 0.29 mmol) and compound 16 
(0.25 g, 0.27 mmol). Afterwards, dry toluene (15 mL) and a solution of KHMDS in toluene 
(1M, 2.5 mL) were added. The reaction mixture was stirred at room temperature for 12 hours, 
heated to 80 ºC and maintained at this temperature for 3 hours. All manipulations were carried 
out under argon. The mixture was then cooled to room temperature and filtered off through  
a Celite 512 layer. The filtrate was concentrated and dried. Flash silica gel chromatography 
(DCM/iPrOH) enabled separation of product 20.  
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Variant II: A 50 mL flask was charged with ligand 8a (0.10 g, 0.29 mmol) and compound 16 
(0.25 g, 0.27 mmol). Afterwards, dry toluene (15 mL) and a solution of KHMDS in toluene 
(1M, 2.5 mL) were added. The reaction mixture was stirred at room temperature for 36 hours. 
All manipulations were carried out under argon. Thereafter, the mixture was filtered off 
through a Celite 512 layer and then the filtrate was concentrated and dried. Flash silica gel 
chromatography (DCM/iPrOH) enabled the separation of the red product. The product was 
purified by several precipitations from toluene-pentane and finally its 
1
H NMR spectrum 
(Fig.2.14 c) and mass spectrum were recorded. According to mass spectrum the isolated red 
product 21 is the mixture of mononuclear complex and dinuclear diruthenium complexes.  
Two peaks observed in mass spectrum correspond to {[(8a-H)
-
]2Ru(Ind) + H
+
} (calculated for 
C55H56N4O2Ru+H
+
 907.3252, observed 907.3498) and to {[(8a-H)
-
]2Ru(Ind)}2 + H
+
 
(calculated for for C110H112N8O4Ru2+H
+
 1813.697, observed 1813.6917). 
 
3.3.2.5 Coordination of ligand 8a to Rh(I) complex 22 
Variant I: A 25 mL flask was charged with ligand 8a (100 mg, 0.29 mmol) and tBuOK  
(70 mg, 6 mmol) and  toluene (9 mL). Afterwards complex 22 (72 mg, 0.15 mmol) was 
added. The resulting reaction mixture was stirred at room temperature for 24 hours.  
Then mixture was filtered off through a Celite 512 layer and washed with DCM (5 mL).  
The filtrate was concentrated and purified via flash silica gel chromatography (DCM/MeOH). 
The mixture of extended cis and extended trans isomers was isolated as a yellow powder  
(86 mg, molar ratio 4:1). 
 
Variant II: A 25 mL flask was charged with ligand 8a (0.20 g, 0.58 mmol) and tBuOK  
(0.24 g, 1.6 mmol) and chloroform (10 mL), washed through basic Al2O3 (grade I) before use. 
After ca 10 min complex 22 (0.14 g, 0.29 mmol) was added. The resulting yellow reaction 
mixture was stirred at 45 ºC for 5 h and afterwards at room temperature for 24 h.  
Then mixture was filtered off through a Celite 512 layer and washed with DCM (10 mL).  
The filtrate was concentrated and purified via flash silica gel chromatography (DCM/iPrOH). 
The mixture of extended cis and extended trans isomers was isolated as a yellow powder 
(0.16 g, molar ratio 5:1). 
Major isomer: 
1
H-NMR (CDCl3): δ 8.05 (s, 1H), 7.13 (t, J=8.0, 1H), 6.97-6.90 (m, 3H), 6.82 
(d, J=8.0, 1H), 6.73 (t, J=8.0, 1H), 3.97 (d, J=13.5, 1H), 3.90 (d, J=13.5, 1H), 3.88-3.81  
87 
(m, 1H), 3.34-3.30 (m, 1H), 2.97-2.89 (m, 1H), 2.29 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H), 1.17 
(d, J=6.5, 3H). 
 
3.3.2.6 Coordination of ligand 8a to Pd(II) complex 
Variant I: PdCl2 (10 mg, 0.06 mmol) was suspended in pyridine-d5 (1 mL) and stirred  
at 60 ºC for 6 h. After cooling the resulting yellow mixture to room temperature ligand 8a (20 
mg, 0.06 mmol) was added, followed by addition of K2CO3 (50 mg, 0.36 mmol). After one 
hour the yellow mixture turned orange. The reaction mixture was stirred at room temperature 
for 16 h. Afterwards, the mixture was filtered off through a Celite 512 layer and a 
1
H NMR 
spectrum was recorded. 
 
Variant II: PdCl2 (50 mg, 0.29 mmol) was suspended in pyridine (3 mL) and stirred at 60 ºC 
for 6 h. After cooling the resulting yellow mixture to room temperature ligand 8a (98 mg, 
0.29 mmol) was added, followed by addition of K2CO3 (155 mg, 1.12 mmol). After one hour 
yellow mixture turned orange. The reaction mixture was stirred at room temperature for 16 h. 
Afterwards, the mixture was filtered off through a Celite 512 layer and the filtrate was 
concentrated using vacuum. Separation via flash silica gel chromatography (DCM/iPrOH) 
afforded a mixture of unidentified compounds. 
  
 
3.3.3 Synthesis of modified PAMAM dendrimers  
 
Synthesis of 3
rd
 generation PAMAM dendrimer G3-PAMAM(-NH2)32 
The 3
rd
 Generation PAMAM dendrimer G3-PAMAM(-NH2)32 was prepared according to 
Tomalia`s procedure
173
 using ethylenediamine as a core and a building block. M = 6907.9 Da. 
1
H-NMR (CD3OD): δ 4.82 (s), 3.28-3.22 (m, 120H), 2.84-2.75 (m, 120H), 2.75-2.49 (m, 
64H), 2.61-2.54 (m, 60H), 2.40-2.32 (m, 120H). 
 
Synthesis of dendrimer G3-PAMAM(-NH2)32 with salicylaldehyde: 
Variant I using 16 equivalent of salicylaldehyde:  
Dendrimer G3-PAMAM(-NH2)32 (300 mg, 43 μmol) was dissolved in methanol (0.8 mL). 
Afterwards salicylaldehyde (73 μL, 690 μmol) was added. The reaction mixture was stirred  
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at room temperature for 3 h and the solvent was removed using vacuum to give  
G3-PAMAM(-NH2)32
50Sal
. 
1
H-NMR (DMSO-d6): δ 8.45 (bs, 15H), 8.11-7.92 (m, 26H), 7.91-7.68 (m, 38H), 7.37  
(bs, 15H), 7.26 (bs, 15H), 6.82 (bs, 31H), 3.58 (bs, 34H), 3.34 (bs, 36H), 3.13-3.02 (m, 92H), 
2.73-2.52 (m, 138H), 2.41 (bs, 58H), 2.15 (bs, 120H). 
 
Variant II using 32 equivalent of salicylaldehyde: 
Dendrimer G3-PAMAM(-NH2)32 (1.00 g, 0.14 mmol) was dissolved in methanol (2 mL). 
Afterwards salicylaldehyde (0.49 mL, 4.6 mmol) was added. The reaction mixture was stirred 
at room temperature for 3 h and the solvent was removed using vacuum to give  
G3-PAMAM(-NH2)32
100Sal
. 
1
H-NMR (DMSO-d6): δ 8.38 (bs, 25H), 7.32 (bs, 25H), 7.23 (bs, 25H), 6.79 (bs, 50H), 3.53 
(bs, xH), 3.31 (bs, 60H), 3.14-2.97 (m, 69H), 2.73-2.54 (m, 118H), 2.46-2.29 (m, 64H), 2.15 
(bs, 120H). 
 
Immobilization of Ru(II) complex 15 on a G3-PAMAM(-NH2)32
50Sal
 
G3-PAMAM(-NH2)32
50Sal
 (50 mg) was dissolved in MeOH (2 mL). Afterwards ruthenium 
complex 15 (82 mg, 0.97 mmol) dissolved in dry THF (2 mL) was added. Reaction mixture 
was stirred under argon for 24 h. Afterwards the dark purple mixture was concentrated to  
ca 1/3 volume and filtered off. The resulting purple solid was washed with THF and pentane 
and then dried in vacuum. 
 
Immobilization of Ru(II) complex 15 on a G3-PAMAM(-NH2)32
100Sal
 
Dendrimer G3-PAMAM(-NH2)32
100Sal
 (45 mg) was dissolved in CHCl3 (30 mL). Afterwards 
complex 15 (55 mg, 0.065 mmol) dissolved in dry THF (2 mL). The reaction mixture was 
stirred under argon for 24 h. Afterwards the dark purple mixture was concentrated to  
ca 1/8 volume and filtered off. The resulting purple solid was washed with THF and pentane 
and then dried in vacuum. After washing the color of the solid turned to green. 
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Abstract  
 
The research presented in this thesis concerns mainly synthesis and development  
of chiral, bidenatate N-heterocyclic carbene precursors and their potential utilization  
as ancillary ligands for Ru(II), Rh(I), Pd(II) complexes. Since chiral imidazolinium salts are 
having remarkable applications in the area of asymmetric synthesis the usage of chiral Boc-
protected amino acids: L-alanine and L-phenylalanine as starting materials and stereogenic 
center providers were introduced. The experimental work done in this thesis was divided  
into three parts. 
In a first part two synthetic routes leading to imidazolinium salts: (S)-3-(2-
hydroxybenzyl)-1-mesityl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-3-ium chloride 5a and 
(S)-3-(3,5-di-tert-butyl-2-hydroxybenzyl)-1-mesityl-4-methyl-5-oxo-4,5-dihydro-1H-
imidazol-3-ium chloride 5b, (S)- and (R)-1-(2-hydroxybenzyl)-3-mesityl-5-methyl-4,5-
dihydro-1H-imidazol-3-ium chlorides 8a and 8c, (S)- and (R)-1-(3,5-di-tert-butyl-2-
hydroxybenzyl)-3-mesityl-5-methyl-4,5-dihydro-1H-imidazol-3-ium chlorides 8b and 8d, and 
(S)-4-benzyl-3-(2-hydroxybenzyl)-1-mesityl-4,5-dihydro-1H-imidazol-3-ium chloride 13 
were proposed and their syntheses were described. Although the synthetic route to salt 5 
occurred to be troublesome and gave mixture of isomers and by-products the route to salts 8a-d 
and 13 with L-alanine and L-phenylalanine in the heterocycle backbone, respectively, gave 
desired imidazolinium salts and we were able to isolate them with good total yield. Obtained 
final compounds 8a-d and 13 were fully characterized. This synthetic route could serve  
as useful method of obtaining such class of compounds.  
Second part of this dissertation was focused on the coordination of the obtained 
saturated N-heterocyclic carbene ligand 8a to selected Ru(II), Rh(I), and Pd(II) complexes. 
Coordination to the known metathesis reaction Ru-catalysts bis(tricyclohexylphosphine)-
benzylidine ruthenium(II) dichloride 15 and bis(tricyclohexylphosphine)-3-phenyl-1H-inden-
1-ylideneruthenium(II) dichloride 16 and to tris(triphenylphosphine) ruthenium(II) dichloride 
19 by in situ deprotonation of the NHC salt in presence of strong bases should give easy 
access to novel bidentate NHC-Ru catalysts. Hovewer only promising results were obtained 
with complex 16 when KHMDS was used as a base. All other experiments led to undefined 
mixture of products.  
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In case of Rh-complexes, we used bis(1,5-cyclooctadiene)dirhodium (I) dichloride complex 
(23) as starting material and we were able to isolate mixture of two isomers, probably 
extended cis and extended trans dirhodium complexes in a molar ratio 5:1.  
Coordination to palladium(II) lead to mixture of products as well.  
Concluding, usage of obtained class of NHC precursors as ancillary ligands for Ru, Rh and Pd 
complexes leads to mixture of products, that are difficult for separation due to chemical 
resemblance (Rh, Pd) or quick decomposition (Ru). 
In a third part attempts to obtain Ru-catalysts immobilized on a periphery modified  
3
rd
 generation PAMAM dendrimer were described. The synthesis of 3
rd
 generation PAMAM 
dendrimers is a known divergent method. Condensation of outer -NH2 groups with salicyl 
aldehyde easily provided PAMAM dendrimers with Schiff bases on their surface. The amount 
of consumed -NH2 groups could be monitored by 
1
H NMR experiments. Coordination  
of Ru complex 15 to modified dendrimer gave catalyst in a form of violet powder. This 
however showed poor catalytic activity towards standard RCM (Ring Closing Metathesis) 
reaction of diethyl diallyl malonate.  
 
 
Keywords: chiral N-heterocyclic carbenes, Ru-complexes, modified PAMAM dendrimers 
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Streszczenie 
 
W przedstawionej pracy opisano badania nad otrzymaniem chiralnych, bidentnych 
prekursorów N-heterocyklicznych karbenów w postaci soli imidazoliniowych oraz zbadanie 
możliwości ich zastosowania jako potencjalnych bidentnych ligandów kompleksów Ru(II), 
Rh(I) i Pd(II). Jako materiał wyjściowy do otrzymania soli imidazoliniowych posiadających 
centrum stereogeniczne zastosowano chiralne aminokwasy L-alaninę oraz L-fenyloalaninę  
w których grupa aminowa zablokowana jest grupą  tert-butoksykarbonylową (Boc).  
Część badawcza pracy została podzielona na trzy części. 
W pierwszej części zaplanowano i opisano dwie ścieżki syntetyczne prowadzące  
do otrzymania następujących soli imidazoliniowych: chlorku (S)-3-(2-hydroksybenzylo)-1-
mesitylo-4-methylo-5-oxo-4,5-dihydro-1H-imidazolu 5a i chlorku (S)-3-(3,5-di-tert-butylo-2-
hydroksybenzylo)-1-mesitylo-4-methylo-5-oxo-4,5-dihydro-1H-imidazolu 5b oraz chlorki 
(S)- i (R)-1-(2-hydroksybenzylo)-3-mesitylo-5-methylo-4,5-dihydro-1H-imidazolu 8a i 8c, 
chlorki (S)- i (R)-1-(3,5-di-tert-butylo-2-hydroksybenzylo)-3-mesitylo-5-methylo-4,5-
dihydro-1H-imidazolu 8b i 8d i chlorku (S)-4-benzylo-3-(2-hydroksybenzylo)-1-mesitylo-
4,5-dihydro-1H-imidazolu 13. W pięcioetapowej syntezie otrzymano z dobrą całkowitą 
wydajnością sole 8a-d oraz 13 z odpowiednio Boc-L alaniny, Boc-D-alaniny oraz Boc-L-
fenyloalaniny. Otrzymane produkty końcowe 8a-d oraz 13 zostały scharakteryzowane  
za pomocą spektroskopii NMR, MS oraz IR. Opisana ścieżka syntetyczna może zostać 
wykorzystana do otrzymywania tej grupy związków. W reakcji pochodnych: chlorowodorku 
(S)-2-(2-hydroksybenzylamino)-N-mesitylopropanamidu 4a oraz chlorowodorku (S)-2-(3,5-
di-tert-butyl-2-hydroksybenzylamino)-N-mesitylopropanamidu 4b z ortomrówczanem trietylu 
otrzymywano mieszaninę izomerów lub inne produkty uboczne.  
W części drugiej opisano próby zastosowania otrzymanej soli 8a jako bidentnego 
liganda wybranych kompleksów Ru(II), Rh(I) oraz Pd(II). Jako związki wyjściowe 
zastosowano znane rutenowe katalizatory reakcji metatezy olefin: dichlorek 
bis(tricykloheksylofosfino)benzylideno rutenu(II) 15 i dichlorek bis(tricykloheksylofosfino)-
3-phenyl-1H-inden-1-ylideno rutenu(II) 16 oraz kompleks dichlorku tris(trifenylofosfiny) 
rutenu(II) 19. Zastosowano metodę deprotonowania in situ otrzymanej soli 8a w obecności 
silnej zasady. Planowano otrzymać nowe katalizatory rutenowe z bidentnym ligandem NHC 
koordynującym do atomu metalu za pomocą atomów C i O. Obiecujące wyniki otrzymano  
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w reakcji kompleksu 16 z ligandem 8a w obecności KHMDS (heksametylenodisilazian 
potasu). We wszystkich innych eksperymentach uzyskiwano niezdefiniowaną mieszaninę 
produktów. Jako materiał wyjściowy do otrzymywania kompleksów rodu wykorzystano 
dichlorek bis(1,5-cyklooctadienu)dirodu(I) 23. Wyizolowano mieszaninę izomerów, 
najprawdopodobniej kompleksów dirodu cis i trans w stosunku molowym 5:1.  
Próby koordynacji liganda 8a do kompleksów Pd(II) prowadziły do otrzymywania 
mieszaniny produktów, której nie udało się rozdzielić. 
Podsumowując, zastosowanie otrzymanych prekursorów N-heterocyklicznych karbenów jako 
ligandów Ru, Rh i Pd prowadzi do otrzymania mieszaniny produktów, które są trudne  
do wyizolowania ze względu na chemiczne podobieństwo (Rh, Pd) lub ze względu na szybki 
rozkład otrzymanych związków (Ru). 
 W części trzeciej opisano próby immobilizacji katalizatora rutenowego  
na peryferycznie zmodyfikowanym dendrymerze typu PAMAM 3-ciej generacji. Dendrymer 
typu PAMAM 3-ej generacji otrzymano stosując znaną metodę rozbieżną. W wyniku 
kondensacji peryferyjnych grup NH2 dendrymeru z aldehydem salicylowym otrzymano 
dendrymery  z zasadami Schiffa na zewnętrznej powierzchni dendrymeru. Ilość utworzonych 
zasad w stosunku do nieprzereagowanych grup NH2 oznaczano za pomocą spektroskopii  
1
H NMR. W reakcji zmodyfikowanego dendrymeru i kompleksu rutenu 15 otrzymywano 
katalizator w postaci fioletowego proszku. Otrzymany katalizator wykazywał słabą 
aktywność katalityczną w reakcji metatycznego zamykania pierścienia, RCM (Ring Closing 
Metathesis) diallilomalonianu dietylu. 
 
 
Słowa kluczowe: chiralne karbeny N-heterocykliczne, kompleksy rutenu, modyfikowane 
dendrymery PAMAM 
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